AU2006308889A1 - GABA receptor mediated modulation of neurogenesis - Google Patents

GABA receptor mediated modulation of neurogenesis Download PDF

Info

Publication number
AU2006308889A1
AU2006308889A1 AU2006308889A AU2006308889A AU2006308889A1 AU 2006308889 A1 AU2006308889 A1 AU 2006308889A1 AU 2006308889 A AU2006308889 A AU 2006308889A AU 2006308889 A AU2006308889 A AU 2006308889A AU 2006308889 A1 AU2006308889 A1 AU 2006308889A1
Authority
AU
Australia
Prior art keywords
gaba
agent
cas
combination
neurogenesis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2006308889A
Other languages
English (en)
Inventor
Carrolee Barlow
Todd A. Carter
Kym I. Lorrain
Andrew Morse
Jammieson C. Pires
Kai Treuner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Braincells Inc
Original Assignee
Braincells Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Braincells Inc filed Critical Braincells Inc
Publication of AU2006308889A1 publication Critical patent/AU2006308889A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2006308889A 2005-10-31 2006-10-30 GABA receptor mediated modulation of neurogenesis Abandoned AU2006308889A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US73194705P 2005-10-31 2005-10-31
US60/731,947 2005-10-31
PCT/US2006/042426 WO2007053596A1 (en) 2005-10-31 2006-10-30 Gaba receptor mediated modulation of neurogenesis

Publications (1)

Publication Number Publication Date
AU2006308889A1 true AU2006308889A1 (en) 2007-05-10

Family

ID=37776885

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006308889A Abandoned AU2006308889A1 (en) 2005-10-31 2006-10-30 GABA receptor mediated modulation of neurogenesis

Country Status (6)

Country Link
US (1) US20070112017A1 (cg-RX-API-DMAC7.html)
EP (2) EP2314289A1 (cg-RX-API-DMAC7.html)
JP (1) JP2009513672A (cg-RX-API-DMAC7.html)
AU (1) AU2006308889A1 (cg-RX-API-DMAC7.html)
CA (1) CA2625210A1 (cg-RX-API-DMAC7.html)
WO (1) WO2007053596A1 (cg-RX-API-DMAC7.html)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2819303T3 (es) * 2005-04-05 2021-04-15 Univ Yale Agentes moduladores del glutamato en el tratamiento de trastornos mentales
WO2007008758A2 (en) * 2005-07-08 2007-01-18 Braincells, Inc. Methods for identifying agents and conditions that modulate neurogenesis
US20070099947A1 (en) * 2005-11-03 2007-05-03 Alkermes, Inc. Methods and compositions for the treatment of brain reward system disorders by combination therapy
US7858611B2 (en) 2006-05-09 2010-12-28 Braincells Inc. Neurogenesis by modulating angiotensin
EP2021000A2 (en) * 2006-05-09 2009-02-11 Braincells, Inc. Neurogenesis by modulating angiotensin
US7678808B2 (en) 2006-05-09 2010-03-16 Braincells, Inc. 5 HT receptor mediated neurogenesis
US20090197823A1 (en) * 2006-05-09 2009-08-06 Braincells, Inc. Aliskiren modulation of neurogenesis
WO2007139818A2 (en) * 2006-05-22 2007-12-06 The Board Of Trustees Of The Leland Stanford Junior University Pharmacological treatment of cognitive impairment
AU2007299726A1 (en) * 2006-09-22 2008-03-27 Braincells, Inc. Combination comprising an HMG-COA reductase inhibitor and a second neurogenic agent for treating a nervous system disorder and increasing neurogenesis
WO2008042795A2 (en) * 2006-09-29 2008-04-10 The Board Of Trustees Of The University Of Illinois Histone acetyle transferase activators and histone deacetylase inhibitors in the treatment of alcoholism
DK2083811T3 (en) * 2006-11-22 2017-01-30 Clinical Res Ass Llc PROCEDURES FOR TREATING DOWNS SYNDROME, FRAGILT X SYNDROME AND AUTISM
TWI433674B (zh) 2006-12-28 2014-04-11 Infinity Discovery Inc 環杷明(cyclopamine)類似物類
CA2675132A1 (en) * 2007-01-11 2008-07-17 Braincells, Inc. Modulation of neurogenesis with use of modafinil
WO2008097861A2 (en) * 2007-02-02 2008-08-14 Braincells, Inc. MODULATION OF NEUROGENESIS WITH BIGUANIDES AND GSK3-ß AGENTS
US20090269795A1 (en) * 2007-03-09 2009-10-29 The Research Foundation Of State University Of New York Mutant alpha4betadelta GABAA receptor and methods of treating anxiety or irritability
WO2008154044A1 (en) * 2007-06-15 2008-12-18 University Of Florida Research Foundation Therapeutic compounds and methods of use
WO2009016329A1 (en) * 2007-07-31 2009-02-05 Cambridge Enterprise Limited Use of gabaa receptor antagonists to treat cognitive impairment in patients with psychiatric conditions
CA2719824A1 (en) * 2007-08-01 2009-02-05 Medivation Neurology, Inc. Methods and compositions for treating schizophrenia using antipsychotic combination therapy
CA2708780A1 (en) * 2007-12-11 2009-06-18 Research Development Foundation Small molecules for neuronal differentiation of embryonic stem cells
JP2011522773A (ja) * 2007-12-27 2011-08-04 インフィニティ ファーマスーティカルズ、インク. 治療剤での癌の処置方法
WO2009086451A1 (en) 2007-12-27 2009-07-09 Infinity Pharmaceuticals, Inc. Methods for stereoselective reduction
EP2135607A1 (en) 2008-06-18 2009-12-23 Pharnext Combination of pilocarpin and methimazol for treating Charcot-MarieTooth disease and related disorders
JP2010018562A (ja) * 2008-07-11 2010-01-28 Kitasato Institute トリパノソーマ原虫類の感染予防・治療剤
US8555875B2 (en) * 2008-12-23 2013-10-15 Map Pharmaceuticals, Inc. Inhalation devices and related methods for administration of sedative hypnotic compounds
US10206921B2 (en) * 2009-06-03 2019-02-19 The Regents Of The University Of California Methods and compositions for treating a subject for central nervous system (CNS) injury
CA2769795C (en) 2009-08-05 2020-01-07 Infinity Pharmaceuticals, Inc. Enzymatic transamination of cyclopamine analogs
EP2322163A1 (en) * 2009-11-03 2011-05-18 Pharnext New therapeutics approaches for treating alzheimer disease
US9387206B2 (en) 2009-11-03 2016-07-12 Pharnext Therapeutic approaches for treating Alzheimer's disease
US20110135611A1 (en) * 2009-12-03 2011-06-09 The J. David Gladstone Institutes Methods for treating apolipoprotein e4-associated disorders
WO2011071995A2 (en) 2009-12-08 2011-06-16 Case Western Reserve University Compounds and methods of treating ocular disorders
US20130150351A1 (en) * 2010-06-03 2013-06-13 Stanley T. Carmichael Methods and compositions for treating a subject for central nervous system (cns) injury
MX353096B (es) 2010-08-19 2017-12-19 Buck Institute For Age Res Star Metodos para tratar el deterioro cognitivo leve (mci) y trastornos relacionados.
US9376447B2 (en) 2010-09-14 2016-06-28 Infinity Pharmaceuticals, Inc. Transfer hydrogenation of cyclopamine analogs
AU2011328993B2 (en) 2010-11-15 2017-03-02 Agenebio, Inc. Pyridazine derivatives, compositions and methods for treating cognitive impairment
JP5916370B2 (ja) * 2010-12-27 2016-05-11 株式会社サンアロマ 内分泌系に作用するストレス応答緩和剤、内分泌系に作用するストレス応答に起因する諸症状を緩和あるいは抑制する緩和剤あるいは抑制剤
US9241933B2 (en) 2011-03-01 2016-01-26 Pharnext Compositions for treating amyotrophic lateral sclerosis
RS53227B (sr) 2011-03-01 2014-08-29 Pharnext Terapija neuroloških poremećaja kombinacijom baklofena i akamprosata
US9248111B2 (en) 2011-03-01 2016-02-02 Pharnext Therapeutic approaches for treating parkinson's disease
US10010515B2 (en) 2011-03-01 2018-07-03 Pharnext Therapeutic approaches for treating Parkinson's disease
US9193710B2 (en) 2011-08-29 2015-11-24 Sanford-Burnham Medical Research Institute Benzodiazepinones as modulators of metabotropic glutamate receptor functions and neurological uses thereof
CA2865318A1 (en) * 2012-02-24 2013-08-29 The United States Government As Represented By The Department Of Veterans Affairs Methods of increasing light responsiveness in a subject with retinal degeneration
EP2705843A1 (en) * 2012-09-05 2014-03-12 Pharnext Therapeutic approaches for treating epilepsy and related disorders through reduction of epileptogenesis
US20150313868A1 (en) 2012-12-18 2015-11-05 Kotzker Consulting Llc Use of cannabinoids and terpenes for treatment of organophosphate and carbamate toxicity
US8992951B2 (en) 2013-01-09 2015-03-31 Sapna Life Sciences Corporation Formulations, procedures, methods and combinations thereof for reducing or preventing the development, or the risk of development, of neuropathology as a result of trauma
WO2014153180A1 (en) * 2013-03-14 2014-09-25 Michela Gallagher Methods and compositions for improving cognitive function
EP4032889B1 (en) 2013-12-20 2026-05-06 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
AU2015317877A1 (en) * 2014-09-15 2017-05-04 Sound Pharmaceuticals Incorporated Methods and compositions for treating psychotic disorders
BR112017026103B1 (pt) 2015-06-04 2023-10-03 Sol-Gel Technologies Ltd Composições tópicas com composto inibidor de hedgehog, sistema de entrega tópica e seus usos
EP3310785B1 (en) 2015-06-19 2024-11-20 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
CN107708446A (zh) 2015-06-22 2018-02-16 雀巢产品技术援助有限公司 用于增强动物体内神经形成的组合物和方法
CN108024997A (zh) 2015-07-17 2018-05-11 奥维德医疗公司 用加波沙朵治疗发育障碍的方法
AU2017216288B2 (en) * 2016-02-05 2022-06-02 Pharnext Novel combinatorial therapies of neurological disorders
KR20230050474A (ko) 2016-08-11 2023-04-14 오비드 테라퓨틱스 인크. 간질 장애의 치료를 위한 방법 및 조성물
US10449181B2 (en) 2016-08-25 2019-10-22 Sarah E. Labance Treatment of autism and autism spectrum disorders (ASD)
CN107974463B (zh) * 2016-10-20 2023-02-17 上海南方模式生物科技股份有限公司 Slc6a11基因及其蛋白的用途
US20180170941A1 (en) 2016-12-19 2018-06-21 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US10071083B2 (en) 2017-02-03 2018-09-11 Ovid Therapeutics Inc Use of gaboxadol in the treatment of tinnitus
WO2018195067A1 (en) 2017-04-17 2018-10-25 The University Of Chicago Polymer materials for delivery of short-chain fatty acids to the intestine for applications in human health and treatment of disease
CA3071939A1 (en) 2017-08-04 2019-02-07 Ovid Therapeutics Inc. Use of gaboxadol in the treatment of diabetes and related conditions
KR101841654B1 (ko) 2017-12-19 2018-03-26 (주)나노스템 콜린 알포세레이트를 유효성분으로 하는 신경병증성 통증의 치료, 개선 또는 예방용 조성물 및 방법
AU2019288382B2 (en) 2018-06-19 2024-07-25 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US10562930B1 (en) 2018-08-31 2020-02-18 Praxis Precision Medicines, Inc. Salts and crystal forms of GABAA positive allosteric modulator
EP3833351A4 (en) 2018-09-20 2021-10-13 Ovid Therapeutics Inc. USE OF GABOXADOL TO TREAT TOURETTE SYNDROME, TICKS, AND STUTTERS
US20210393621A1 (en) 2018-10-26 2021-12-23 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
MX2021007224A (es) 2018-12-17 2021-09-23 Ovid Therapeutics Inc Uso de gaboxadol para el tratamiento del trastorno del sue?o vigilia que no es de 24 horas.
US12636291B2 (en) 2019-02-13 2026-05-26 Centre For Addiction And Mental Health Compositions and methods relating to use of agonists of ALPHA5-containing GABAA receptors
US11364228B2 (en) 2019-12-18 2022-06-21 Ovid Therapeutics Inc. Gaboxadol for therapeutic treatment of 1p36 deletion syndrome
US20240139205A1 (en) * 2020-03-05 2024-05-02 Universite De Lausanne Modulators of aralar for treating neurological disorders
JP7821116B2 (ja) * 2020-04-07 2026-02-26 ザ トラスティーズ オブ コロンビア ユニバーシティー イン ザ シティー オブ ニューヨーク ストレス誘導性恐怖、うつ様行動および不安様行動の予防のための組成物および方法
US11969434B1 (en) 2022-08-29 2024-04-30 Lipocine Inc. Oral allopregnanolone compositions and methods of use
CN114586985A (zh) * 2022-03-16 2022-06-07 黑龙江省科学院高技术研究院 γ-氨基丁酸在制备缓解精神分裂症患者焦虑情绪的食品中的应用及制备的食品
US12186327B2 (en) 2022-08-29 2025-01-07 Lipocine Inc. Oral allopregnanolone compositions and methods of use

Family Cites Families (724)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3121076A (en) * 1964-02-11 Benzodiazepinones and processes
US58665A (en) 1866-10-09 Improvement in the manufacture of spoons
US666073A (en) 1900-10-29 1901-01-15 Harry Simmons Sectional legal-blank file.
GB235187A (en) 1924-06-07 1926-06-03 Robert Howe Gould Improvements in burglar and like alarms
US1873732A (en) 1928-12-28 1932-08-23 Abbott Lab Bactericide applicable to acid-fast bacteria
US3136815A (en) * 1959-12-10 1964-06-09 Hoffmann La Roche Amino substituted benzophenone oximes and derivatives thereof
US3371085A (en) 1959-12-10 1968-02-27 Hoffmann La Roche 5-aryl-3h-1,4-benzodiazepin-2(1h)-ones
US3454554A (en) 1960-10-14 1969-07-08 Colgate Palmolive Co Aminoalkyliminodibenzyl compounds
US3116203A (en) 1962-03-14 1963-12-31 Hoffmann La Roche Oleaginous systems
NL298071A (cg-RX-API-DMAC7.html) * 1963-06-04
CH449645A (de) 1963-07-09 1968-01-15 Ciba Geigy Verfahren zur Herstellung neuer Aminosäuren
CH427803A (de) * 1963-12-06 1967-01-15 Geigy Ag J R Verfahren zur Herstellung eines neuen Isoxazolderivates
NL129434C (cg-RX-API-DMAC7.html) 1966-03-12
US3397209A (en) 1966-11-25 1968-08-13 Geigy Chem Corp 3-hydroxy-5-isoxazole-carboxamide
US3885046A (en) 1969-12-04 1975-05-20 Burroughs Wellcome Co Meta chloro or fluoro substituted alpha-T-butylaminopropionphenones in the treatment of depression
BE759838A (fr) 1969-12-04 1971-06-03 Wellcome Found Cetones a activite biologique
FR2077918B1 (cg-RX-API-DMAC7.html) 1970-02-24 1973-04-06 Berthier Laboratoires
US3821249A (en) 1970-03-13 1974-06-28 En Nom Collectif Science Union Dibenzothiazefin derivatives
US3758528A (en) 1970-03-13 1973-09-11 Science Union & Cie Tricyclic compounds
US3819631A (en) 1970-12-15 1974-06-25 May & Baker Ltd Azapurinones
OA04285A (fr) 1972-01-07 1979-12-31 Rhone Poulenc Sa Nouveaux dérivés de la pyrrolo (3,4-b) pyrazine et leur préparation.
USRE31617E (en) 1972-02-04 1984-06-26 Bristol-Myers Company Optionally substituted 1,2,3,5-tetrahydroimidezo(2,1-b)-quinazolin-2-ones and 6(H)-1,2,3,4-tetrahydropyimido(2,1-b)quinazolin-2-ones
US3932407A (en) 1973-11-19 1976-01-13 Bristol-Myers Company Optionally substituted 1,2,3,5-tetrahydroimidezo(2,1-b)-quinazolin-2-ones and 6(H)-1,2,3,4-tetrahydropyimido(2,1-b)quinazolin-2-ones
US4036840A (en) 1972-06-07 1977-07-19 Icn Pharmaceuticals 2-Substituted-s-triazolo[1,5a]pyrimidines
GB1457873A (en) 1973-01-04 1976-12-08 Allen & Hanburys Ltd Imidazotriazines
GB1422263A (en) 1973-01-30 1976-01-21 Ferrosan As 4-phenyl-piperidine compounds
US4051236A (en) 1973-02-15 1977-09-27 E. R. Squibb & Sons, Inc. Inhibition of blood platelet aggregation
US4314081A (en) 1974-01-10 1982-02-02 Eli Lilly And Company Arloxyphenylpropylamines
US4194009A (en) 1974-01-10 1980-03-18 Eli Lilly And Company Aryloxyphenylpropylamines for obtaining a psychotropic effect
US4280957A (en) * 1974-09-11 1981-07-28 Hoffmann-La Roche Inc. Imidazodiazepines and processes therefor
AR208414A1 (es) 1974-11-07 1976-12-27 Rhone Poulenc Ind Procedimiento para obtener nuevos derivados de la((acil-4piperazinil-1)carboniloxi-5 pirrolinona-2)
US4093617A (en) 1974-11-12 1978-06-06 Icn Pharmaceuticals, Inc. 3,5,7-Trisubstituted pyrazolo[1,5-a]pyrimidines
DE2460891C2 (de) 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US3960927A (en) 1975-03-18 1976-06-01 Richardson-Merrell Inc. Olefinic derivatives of amino acids
NL7503310A (nl) 1975-03-20 1976-09-22 Philips Nv Verbindingen met antidepressieve werking.
NL189199C (nl) 1975-04-05 1993-02-01 Akzo Nv Werkwijze ter bereiding van farmaceutische preparaten met werking op het centraal zenuwstelsel op basis van benz(aryl)azepinederivaten, de verkregen gevormde farmaceutische preparaten, alsmede werkwijze ter bereiding van de toe te passen benz(aryl)azepinederivaten.
GB1497306A (en) 1975-07-03 1978-01-05 Leo Ab Preparation of lofepramine and its hydrochloride
FR2319338A1 (fr) 1975-08-01 1977-02-25 Synthelabo Nouveaux derives de a- phenyl benzylideniques des acides amines, leur preparation et les medicaments qui en contiennent
GB1526331A (en) 1976-01-14 1978-09-27 Kefalas As Phthalanes
YU96177A (en) 1976-04-24 1982-08-31 Wuelfing Johann A Process for obtaining adenine derivatives
USRE30511E (en) 1977-02-03 1981-02-10 American Cyanamid Company Imidazo[1,5-d]-as-triazine-4(3H)-ones and thiones
US4107307A (en) 1977-02-03 1978-08-15 American Cyanamid Company Imidazo [1,5-d]-as-triazine-4(3H)-ones and thiones
US4404380A (en) 1977-02-14 1983-09-13 Mead Johnson & Company Triazolopyrimidines
CA1095906A (en) 1977-02-14 1981-02-17 Davis L. Temple, Jr. Heterocyclopyrimidines, compositions and therapeutic process
US4096257A (en) 1977-05-23 1978-06-20 American Cyanamid Company Substituted imidazo [1,2-d]-as-triazines
US4107309A (en) 1977-05-23 1978-08-15 American Cyanamid Company Substituted imidazo[1,2-d]-as-triazines
IN148482B (cg-RX-API-DMAC7.html) 1977-06-03 1981-03-07 Pfizer
DK270378A (da) * 1977-06-20 1978-12-21 Krogsgaard Larsen P Isoxazolderivater
US4370328A (en) 1977-11-03 1983-01-25 Pfizer Inc. Cardiac stimulant 1-(3- or 4-substituted piperidino)phthalazines
CA1086735A (en) 1977-11-03 1980-09-30 John C. Danilewicz Piperidino-quinazolines
IL56369A (en) 1978-01-20 1984-05-31 Erba Farmitalia Alpha-phenoxybenzyl propanolamine derivatives,their preparation and pharmaceutical compositions comprising them
US4146718A (en) 1978-04-10 1979-03-27 Bristol-Myers Company Alkyl 5,6-dichloro-3,4-dihydro-2(1h)-iminoquinazoline-3-acetate hydrohalides
US4366156A (en) 1979-03-05 1982-12-28 Mead Johnson & Company Antiallergic methods using diazaheterocyclopurines
CA1143728A (en) 1979-10-04 1983-03-29 Max Gerecke Imidazodiazepine derivatives
US4536518A (en) 1979-11-01 1985-08-20 Pfizer Inc. Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine
JPS5668695A (en) 1979-11-10 1981-06-09 Sankyo Co Ltd Enzyme inhibitor griseolic acid and its preparation
US4642345A (en) 1980-08-14 1987-02-10 Mead Johnson & Company 6,7-dihydro-3H-imidazo[1,2-a]-purine-9(4H)-ones
US4301176A (en) 1980-08-18 1981-11-17 Warner-Lambert Company Method of administering calcium valproate
US4361583A (en) 1980-08-19 1982-11-30 Synthelabo Analgesic agent
FR2492258A1 (fr) 1980-10-17 1982-04-23 Pharmindustrie Nouveau medicament a base d'amino-2 trifluoromethoxy-6 benzothiazole
FR2492382A1 (fr) 1980-10-22 1982-04-23 Synthelabo Derives d'imidazo (1,2-a) pyridine, leur preparation et leur application en therapeutique
US4489078A (en) 1980-11-24 1984-12-18 Mead Johnson & Company Diazaheterocyclopurines used as anti-broncho spasmatics and vasodilators
US4338317A (en) 1981-03-16 1982-07-06 Mead Johnson & Company Phenoxyethyl-1,2,4,-triazol-3-one antidepressants
US4383999A (en) * 1981-05-26 1983-05-17 Smithkline Beckman Corporation Inhibition of GABA uptake by N-substituted azaheterocyclic carboxylic acids and their esters
FR2508035A1 (fr) 1981-06-23 1982-12-24 Fabre Sa Pierre Derives d'aryl-1-aminomethyl-2 cyclopropanes carboxamides (z), leur preparation et leur application en tant que medicaments utiles dans le traitement des troubles du systeme nerveux central
LU83729A1 (fr) 1981-11-04 1983-09-01 Galephar Sels d'acide valproique,leur preparation et leur utilisation
US4513135A (en) 1982-03-05 1985-04-23 Eli Lilly And Company Diaryl-pyrazine derivatives affecting GABA binding
CH655110A5 (de) 1982-09-03 1986-03-27 Otsuka Pharma Co Ltd Carbostyrilderivate, verfahren zu deren herstellung und arzneimittel, welche diese enthalten.
US4663320A (en) 1983-02-16 1987-05-05 Syntex (U.S.A.) Inc. (2-oxo-1,2,3,5-tetrahydroimidazo[2,1-b]quinoazolinyl)oxyalkylamides, compositions and the use thereof
US4490371A (en) 1983-02-16 1984-12-25 Syntex (U.S.A.) Inc. N,N-Disubstituted-(2-oxo-1,2,3,5-tetrahydroimidazo-[2,1-B]quinazolinyl)oxyalkylamides
US4521422A (en) 1983-06-23 1985-06-04 American Cyanamid Company Aryl and heteroaryl[7-(aryl and heteroaryl)pyrazolo[1,5-a]pyrimidin-3-yl]methanones
US4900836A (en) * 1983-06-23 1990-02-13 American Cyanamid Company (3-amino-1H-pyrazol-4-yl) (aryl)methanones
US4626538A (en) 1983-06-23 1986-12-02 American Cyanamid Company [7-(3-disubstituted amino)phenyl]pyrazolo[1,5-a]pyrimidines
US4513006A (en) 1983-09-26 1985-04-23 Mcneil Lab., Inc. Anticonvulsant sulfamate derivatives
US4761501A (en) 1983-10-26 1988-08-02 American Home Products Corporation Substituted phenylacetamides
US4593029A (en) 1984-02-15 1986-06-03 Syntex (U.S.A.) Inc. Novel ω-(N-imidazolyl)alkyl ethers of 1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-2-ones
GB8425872D0 (en) * 1984-10-12 1984-11-21 Ciba Geigy Ag Chemical compounds
US4855290A (en) 1985-05-10 1989-08-08 State Of Israel, Represented By Prime Minister's Office, Israel Institute For Biological Research Derivatives of quinuclidine
DK288385D0 (da) 1985-06-26 1985-06-26 Novo Industri As Aminosyrederivater
DE3677316D1 (de) 1985-10-17 1991-03-07 Smith Kline French Lab 4(4-oxo-1,4-dihydropyridin-1-yl)phenyl-derivate.
US4670434A (en) 1985-11-14 1987-06-02 Syntex (U.S.A.) Inc. (2-oxo-3-methylene-1,2,3,5-tetrahydroimidazo[2,1-b]quinazolinyl)oxyalkylamides useful as cyclic AMP phosphodiesterase inhibitors
US4775674A (en) 1986-05-23 1988-10-04 Bristol-Myers Company Imidazoquinolinylether derivatives useful as phosphodiesterase and blood aggregation inhibitors
FR2600650B1 (fr) 1986-06-27 1988-09-09 Synthelabo Procede de preparation d'imidazopyridines et composes intermediaires
US4701459A (en) 1986-07-08 1987-10-20 Bristol-Myers Company 7-amino-1,3-dihydro-2H-imidazo[4,5-b]quinolin 2-ones and method for inhibiting phosphodiesterase and blood platelet aggregation
US5312840A (en) 1986-07-10 1994-05-17 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education Substituted guanidines having high binding to the sigma receptor and the use thereof
US5093525A (en) 1986-07-10 1992-03-03 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University N,N'-disubstituted guanidines and their use as excitatory amino acid antagonists
US4709094A (en) 1986-07-10 1987-11-24 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon Sigma brain receptor ligands and their use
US5385946A (en) 1986-07-10 1995-01-31 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon Method for treating hypertension with disubstituted granidine compounds
US4761416A (en) 1986-07-25 1988-08-02 Syntex (U.S.A.) Inc. N-N-disubstituted-ω-[2-amino-3-(carbonylmethyl)-3, 4-dihydroquinazolinyl]oxyalkylamides and related compounds
US4739056A (en) 1986-11-26 1988-04-19 Syntex (U.S.A.) Inc. N-N-disubstituted-omega-(2-amino-3-(carbonylmethyl)-3,4-dihydroquinazolinyl)oxy-alkylamides and related compounds
US4786648A (en) 1986-12-08 1988-11-22 Warner-Lambert Company O-substituted tetrahydropyridine oxime cholinergic agents
US4710508A (en) 1986-12-08 1987-12-01 Warner-Lambert Company O-substituted tetrahydropyridine oxime cholinergic agents
US4956388A (en) 1986-12-22 1990-09-11 Eli Lilly And Company 3-aryloxy-3-substituted propanamines
US4721784A (en) 1986-12-22 1988-01-26 Ortho Pharmaceutical Corporation 6-benzoxazinyl-2,3,4,5-tetrahydropyridazin-3-ones
US5081242A (en) 1986-12-22 1992-01-14 Ortho Pharmaceutical Corporation 6-benzoxazinyl- and 6-benzothiazinyl 2,3,4,5-tetrahydropyridazin-3-ones
US4766118A (en) 1986-12-22 1988-08-23 Ortho Pharmaceutical Corporation 6-benzoxazinyl- and 6-benzothiazinyl-2,3,4,5-tetrahydropyridazin-3-ones and pharmaceutical use
US4929734A (en) 1987-03-31 1990-05-29 Warner-Lambert Company Tetrahydropyridine oxime compounds
GB8714789D0 (en) 1987-06-24 1987-07-29 Lundbeck & Co As H Heterocyclic compounds
US4981858A (en) 1987-08-13 1991-01-01 State Of Israel, Represented By The Prime Minister's Office, Israel Institute For Biological Research Optical isomers
US5120723A (en) 1987-08-25 1992-06-09 University Of Southern California Method, compositions, and compounds for modulating brain excitability
US5232917A (en) * 1987-08-25 1993-08-03 University Of Southern California Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
USRE35517E (en) 1987-08-25 1997-05-20 University Of Southern California Method, compositions, and compounds for modulating brain excitability
US5319115A (en) 1987-08-25 1994-06-07 Cocensys Inc. Method for making 3α-hydroxy, 3β-substituted-pregnanes
ATE122353T1 (de) 1987-10-05 1995-05-15 Yamanouchi Pharma Co Ltd Heterozyklische spiroverbindungen und ihre herstellung.
US5412096A (en) 1987-10-05 1995-05-02 Yamanouchi Pharmaceutical Co., Ltd. Hydrochloride salts of heterocyclic spiro compounds
IL88156A (en) 1987-11-13 1997-02-18 Novo Nordisk As Azacyclic compounds their preparation and pharmaceutical compositions containing them
US4831031A (en) 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
US5091431A (en) 1988-02-08 1992-02-25 Schering Corporation Phosphodiesterase inhibitors
US4957916A (en) 1988-08-05 1990-09-18 Janssen Pharmaceutica N.V. Antipsychotic 3-piperazinylbenzazole derivatives
GB8820266D0 (en) 1988-08-26 1988-09-28 Smith Kline French Lab Compounds
US4861891A (en) 1988-08-31 1989-08-29 Pfizer Inc. Antidepressant N-substituted nicotinamide compounds
FR2636625B1 (fr) 1988-09-01 1990-11-09 Jouveinal Sa Benzylamines disubstituees, leur procede de preparation, leur utilisation comme medicament et leurs intermediaires de synthese
DE3839385A1 (de) 1988-11-22 1990-05-23 Boehringer Ingelheim Kg Neue quinuclidine, ihre herstellung als arzneimittel und verfahren zu ihrer herstellung
US5286864A (en) 1988-11-22 1994-02-15 Boehringer Ingelheim Kg Quinuclidines, their use as medicaments and processes for their preparation
US5043345A (en) 1989-02-22 1991-08-27 Novo Nordisk A/S Piperidine compounds and their preparation and use
US4981870A (en) 1989-03-07 1991-01-01 Pfizer Inc. Use of 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine derivatives in the treatment of psychosis, inflammation and as immunosuppressants
US4971972A (en) 1989-03-23 1990-11-20 Schering Corporation Phosphodiesterase inhibitors having an optionally substituted purine derivative portion and a benzo- or cyclopenta-furan portion
US5278170A (en) 1989-04-13 1994-01-11 Beecham Group P.L.C. Azabicylo oxime compounds
ATE269330T1 (de) 1989-04-13 2004-07-15 Beecham Group Plc Chemische verbindungen
DE69011859T2 (de) 1989-05-02 1994-12-15 Oregon State Verwendung von sigma-rezeptor-liganden zur herstellung eines anxiolytikums.
US4956368A (en) 1989-07-24 1990-09-11 Bristol-Myers Company Metabolites and prodrug formulations of 8-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]butyl]-8-azaspiro[4.5]decane-7,9-dione
US5109002A (en) 1989-09-08 1992-04-28 Du Pont Merck Pharmaceutical Company Antipsychotic 1-cycloalkylpiperidines
EP0497843A4 (en) 1989-10-27 1992-09-23 The Du Pont Merck Pharmaceutical Company (n-phthalimidoalkyl) piperidines
US4943573A (en) 1989-11-01 1990-07-24 Bristol-Myers Squibb Company Imidazo[4,5-b]quinolinyloxyalkanoic acid amides with enhanced water solubility
US5010086A (en) 1990-02-28 1991-04-23 Sterling Drug Inc. Imidazopyridines, compositions and use
US4963561A (en) 1990-02-28 1990-10-16 Sterling Drug Inc. Imidazopyridines, their preparation and use
US5149817A (en) 1990-03-05 1992-09-22 Shionogi & Co., Ltd. Teirahydropyridine derivatives
US5169855A (en) 1990-03-28 1992-12-08 Du Pont Merck Pharmaceutical Company Piperidine ether derivatives as psychotropic drugs or plant fungicides
US5116995A (en) 1990-05-25 1992-05-26 Taisho Pharmaceutical Co., Ltd. Carbazole compounds
JPH05508836A (ja) 1990-05-25 1993-12-09 オレゴン州 シグマ受容体に対して高い結合性を有する置換グアニジンおよびその使用
US5612211A (en) 1990-06-08 1997-03-18 New York University Stimulation, production and culturing of hematopoietic progenitor cells by fibroblast growth factors
FR2663328B1 (fr) 1990-06-14 1994-08-05 Sanofi Sa Derives d'hexahydroazepines, un procede pour leur preparation et compositions pharmaceutiques les contenant.
US5250534A (en) 1990-06-20 1993-10-05 Pfizer Inc. Pyrazolopyrimidinone antianginal agents
US5095015A (en) 1990-07-24 1992-03-10 Neurogen Corporation Certain azacycloalkyl imidazopyrimidines; a new class of gaba brain receptor ligands
FR2663934B1 (fr) 1990-06-27 1994-06-03 Adir Nouveaux derives de l'acide 4 - amino butyrique, leur procede de preparation et les preparations pharmaceutiques qui les contiennent.
JP2935541B2 (ja) 1990-06-28 1999-08-16 サントリー株式会社 縮合複素環化合物
US5086054A (en) 1990-07-31 1992-02-04 Sri International Novel arylcycloalkanepolyalkylamines
DK198590D0 (da) 1990-08-21 1990-08-21 Novo Nordisk As Heterocykliske forbindelser, deres fremstilling og anvendelse
GB9019095D0 (en) 1990-09-01 1990-10-17 Beecham Group Plc Novel compounds
US5185446A (en) * 1990-09-04 1993-02-09 Neurogen Corporation Certain cycloalkyl imidazopyrimidines; a new class of gaba brainreceptor ligands
EP0738717A1 (en) 1990-10-09 1996-10-23 Neurogen Corporation Certain substituted pyrimidines as intermediates for production of cycloalkyl and azacycloalkyl pyrrolopyrimidines
EP0552213A1 (en) 1990-10-12 1993-07-28 Beecham Group Plc 1,2,5,6-tetrahydropyridine oxime derivatives
EP0481262B1 (en) 1990-10-15 1995-02-15 Societe Des Produits Nestle S.A. Treatment of black tea
US5139802A (en) 1990-10-15 1992-08-18 Nestec S.A. Oxidation of tea
US5130430A (en) 1990-10-31 1992-07-14 Neurogen Corporation 2-substituted imidazoquinoxaline diones, a new class of gaba brain receptor ligands
US5744602A (en) * 1990-10-31 1998-04-28 Neurogen Corporation Certain imidazoquinoxalines; a new class of GABA brain receptor ligands
US6268496B1 (en) 1990-10-31 2001-07-31 Neurogen Corporation Certain imidazoquinoxalines: a new class of GABA brain receptor ligands
US6197819B1 (en) 1990-11-27 2001-03-06 Northwestern University Gamma amino butyric acid analogs and optical isomers
US5116837A (en) 1990-12-21 1992-05-26 Ortho Pharmaceutical Corporation 2,9-dihydro-(6 or 7)-(3-oxo-2,3,4,5-tetrahydropyridazinyl)-pyrazolo [4,3-B]-1,4-benzoxazines
FR2671800B1 (fr) 1991-01-17 1993-03-12 Rhone Poulenc Rorer Sa Derive de la 5h-pyrrolo[3,4-b]pyrazine optiquement actif, sa preparation et les compositions pharmaceutiques qui le contiennent.
US5180729A (en) 1991-02-22 1993-01-19 Du Pont Merck Pharmaceutical Company Use of sigma receptor antagonists for treatment of cocaine abuse
US5162341A (en) 1991-02-22 1992-11-10 Du Pont Merck Pharmaceutical Company Use of sigma receptor antagonists for treatment of amphetamine abuse
EP0503411B1 (de) 1991-03-14 1995-11-29 BASF Aktiengesellschaft Substituierte N-Phenylpiperidine und Arzneimittel daraus
US5231099A (en) 1991-04-15 1993-07-27 Du Pont Merck Pharmaceutical Company Use of sigma receptor antagonists to enhance the effects of antipsychotic drugs
US5137895A (en) 1991-04-29 1992-08-11 A. H. Robins Company, Incorporated 3-[N-aroyl(or thioaroyl)aminomethyl]-3-quinuclidinols
US5403931A (en) 1991-05-15 1995-04-04 Yamanouchi Pharmaceutical Co., Ltd. (-)-(S)-2,8-dimethyl-3-methylene-1-oxa-8-azaspiro[4.5]decane L-tartrate
US5719057A (en) * 1991-06-11 1998-02-17 Merck Sharpe & Dohme Ltd. Stably human transfected rodent fibroblast cell line expressing human GABA-A recepotors, and cloned human GABA-A receptor subunit CDNA sequences
NZ243065A (en) 1991-06-13 1995-07-26 Lundbeck & Co As H Piperidine derivatives and pharmaceutical compositions
AU676993B2 (en) 1991-06-27 1997-04-10 Virginia Commonwealth University Sigma receptor ligands and the use thereof
US5182290A (en) 1991-08-27 1993-01-26 Neurogen Corporation Certain oxazoloquinolinones; a new class of GABA brain receptor ligands
US5182386A (en) 1991-08-27 1993-01-26 Neurogen Corporation Certain imidazoquinoxalinones; a new class of gaba brain receptor ligands
CA2118938A1 (en) 1991-09-13 1993-04-01 Kelvin W. Gee Novel gabaa receptor with steroid binding sites
PT100905A (pt) 1991-09-30 1994-02-28 Eisai Co Ltd Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem
US5369108A (en) 1991-10-04 1994-11-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
US5585490A (en) 1991-10-08 1996-12-17 Neurogen Corporation Certain cycloalkyl and azacycloalkyl pyrrolopyrimidines; a new class of GABA brain receptor ligands
PH31245A (en) 1991-10-30 1998-06-18 Janssen Pharmaceutica Nv 1,3-Dihydro-2H-imidazoÄ4,5-BÜ-quinolin-2-one derivatives.
WO1993009094A1 (en) 1991-10-30 1993-05-13 The Du Pont Merck Pharmaceutical Company Ether derivatives of alkyl piperidines and pyrrolidines as antipsychotic agents
US5212310A (en) 1991-12-19 1993-05-18 Neurogen Corporation Certain aryl fused imidazopyrimidines; a new class of GABA brain receptor ligands
US5243049A (en) * 1992-01-22 1993-09-07 Neurogen Corporation Certain pyrroloquinolinones: a new class of GABA brain receptor ligands
MX9300875A (es) 1992-02-20 1993-08-31 Smithkline Beecham Plc Procedimiento para la preparacion de compuestos azabiciclicos.
US6225115B1 (en) 1992-03-04 2001-05-01 Synaptic Pharmaceutical Corporation DNA encoding taurine and GABA transporters and uses thereof
US5298657A (en) 1992-03-20 1994-03-29 Cambridge Neuroscience Inc. Preparation of substituted guanidines
US5294612A (en) 1992-03-30 1994-03-15 Sterling Winthrop Inc. 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-ones and compositions and method of use thereof
US5367077A (en) 1992-04-08 1994-11-22 Neurogen Corporation Certain cycloalkyl and azacycloalkyl pyrrolopyridines; a new class of gaba rain receptor ligands
AU4117493A (en) 1992-04-08 1994-11-21 Neurogen Corporation Certain aryl fused pyrrolopyrimidines; a new class of gaba brain receptor ligands
US5266698A (en) 1992-04-30 1993-11-30 Neurogen Corporation Certain aryl and cycloalkyl fused imidazopyrazinediones; a new class of GABA brain receptor ligands
ES2060547B1 (es) 1992-06-04 1995-06-16 Ferrer Int Mejoras en el objeto de la patente de invencion n/ 9201158 que se refiere a "procedimiento de obtencion de nuevos derivados de la 4-bencilpiperidina".
GB9212693D0 (en) 1992-06-15 1992-07-29 Celltech Ltd Chemical compounds
GB9212673D0 (en) 1992-06-15 1992-07-29 Celltech Ltd Chemical compounds
JP2683783B2 (ja) 1992-07-10 1997-12-03 雪印乳業株式会社 シェーグレン症候群治療剤
JP2657760B2 (ja) 1992-07-15 1997-09-24 小野薬品工業株式会社 4−アミノキナゾリン誘導体およびそれを含有する医薬品
US5928947A (en) 1992-07-27 1999-07-27 California Institute Of Technology Mammalian multipotent neural stem cells
US5306819A (en) 1992-08-27 1994-04-26 Neurogen Corporation Certain aryl a cycloalkyl fused imidazopyrazinols; and new class of GABA brain receptor ligands
ZA937382B (en) 1992-10-06 1994-04-29 Warner Lambert Co Novel composition for peroral therapy of cognitionimpairment and a process therefor
GB9222253D0 (en) 1992-10-23 1992-12-09 Celltech Ltd Chemical compounds
US5668283A (en) 1992-11-12 1997-09-16 Neurogen Corporation Certain aryl substituted pyrrolopyrazines; a new class of GABA brain receptor ligands
US5286860A (en) 1992-11-12 1994-02-15 Neurogen Corporation Certain aryl substituted pyrrolopyrazines; a new class of GABA brain receptor ligands
US5814651A (en) 1992-12-02 1998-09-29 Pfizer Inc. Catechol diethers as selective PDEIV inhibitors
WO1994013799A1 (en) * 1992-12-10 1994-06-23 Merck Sharp & Dohme Limited Stably transfected cell lines expressing gaba-a receptors
GB9226830D0 (en) 1992-12-23 1993-02-17 Celltech Ltd Chemical compounds
US5622977A (en) 1992-12-23 1997-04-22 Celltech Therapeutics Limited Tri-substituted (aryl or heteroaryl) derivatives and pharmaceutical compositions containing the same
AU5991294A (en) 1993-01-06 1994-08-15 Neurogen Corporation Certain aryl substituted imidazopyrazinones a new class of gaba brain receptor ligands
US5362860A (en) 1993-02-01 1994-11-08 Warner-Lambert Company Neutral stabilization complex for CI-979 HCl, a cognition activator
US5424301A (en) 1993-02-01 1995-06-13 Warner-Lambert Company Starch stabilized o-substituted tetrahydropyridine oxime cholinergic agents
US6013799A (en) * 1993-03-03 2000-01-11 Neurogen Corporation Certain cycloalkyl imidazopyrimides, a new class of gaba brain receptor ligands
GB9304920D0 (en) 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
GB9304919D0 (en) 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
DK0690850T3 (da) 1993-03-26 1998-02-09 Schering Corp 2-Substituerede morpholin- og thiomorpholinderivater som GABAB-antagonister
US5455252A (en) 1993-03-31 1995-10-03 Syntex (U.S.A.) Inc. Optionally substituted 6,8-quinolines
JP4008024B2 (ja) 1993-05-24 2007-11-14 パーデュー、ファーマ、リミテッド、パートナーシップ Gabaaレセプター複合体と相互作用させるための化合物
US5750702A (en) 1993-10-27 1998-05-12 Neurogen Corporation Certain pyrrolo pyridine-3-carboxamides; a new class of GABA brain receptor ligands
JP3610368B2 (ja) 1993-05-27 2005-01-12 セネス リミティド 治療用置換グアニジン
GB9301192D0 (en) 1993-06-09 1993-06-09 Trott Francis W Flower shaped mechanised table
AU7177694A (en) 1993-06-23 1995-01-17 Cambridge Neuroscience, Inc. Sigma receptor ligands and the use thereof
CZ290266B6 (cs) 1993-07-02 2002-06-12 Byk Gulden Lomberg Chemische Fabrik Gmbh Substituované benzamidy, způsob jejich výroby a farmaceutické prostředky s jejich obsahem
WO1995001997A1 (en) 1993-07-09 1995-01-19 Smithkline Beecham Corporation RECOMBINANT AND HUMANIZED IL-1β ANTIBODIES FOR TREATMENT OF IL-1 MEDIATED INFLAMMATORY DISORDERS IN MAN
ES2074946B1 (es) 1993-07-19 1996-06-16 Ferrer Int Nuevos compuestos derivados de la 1,2-etanodiamina-n,n,n',n'-tetrasustituida.
WO1995004050A1 (en) 1993-07-28 1995-02-09 Santen Pharmaceutical Co., Ltd. Novel 1,4-di(phenylalkyl)piperazine derivative
US5665754A (en) 1993-09-20 1997-09-09 Glaxo Wellcome Inc. Substituted pyrrolidines
US5484944A (en) * 1993-10-27 1996-01-16 Neurogen Corporation Certain fused pyrrolecarboxanilides and their use as GABA brain receptor ligands
CZ283564B6 (cs) 1993-11-26 1998-05-13 Pfizer Inc. 3-Aryl-2-isoxazolin-5-hydroxamové kyseliny a farmaceutické prostředky na jejich bázi
US5502072A (en) 1993-11-26 1996-03-26 Pfizer Inc. Substituted oxindoles
JP2818820B2 (ja) 1993-11-26 1998-10-30 ファイザー・インク. 抗炎症剤としての3−アリール−2−イソオキサゾリン類
US5849760A (en) 1993-12-09 1998-12-15 Institut De Recherche Jouveinal 2-(arylalkenyl)azacycloalkane derivatives as ligands for sigma receptors
US5500420A (en) 1993-12-20 1996-03-19 Cornell Research Foundation, Inc. Metabotropic glutamate receptor agonists in the treatment of cerebral ischemia
EP0738268B1 (en) 1993-12-22 2004-03-03 Celltech R&D Limited Trisubstituted phenyl derivatives, processes for their preparation and their use as phosphodiesterase (type iv) inhibitors
GB9326699D0 (en) 1993-12-22 1994-03-02 Celltech Ltd Chemical compounds
GB9326173D0 (en) 1993-12-22 1994-02-23 Celltech Ltd Chemical compounds and process
US7060450B1 (en) 1993-12-30 2006-06-13 President And Fellows Of Harvard College Screening assays for agonists and antagonists of the hedgehog signaling pathway
GB9514465D0 (en) 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
GB9401090D0 (en) 1994-01-21 1994-03-16 Glaxo Lab Sa Chemical compounds
US5939545A (en) 1994-02-14 1999-08-17 Cocensys, Inc. Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series
DK1038880T3 (da) 1994-02-14 2008-03-03 Euro Celtique Sa Androstaner og pregnaner til allosterisk modulering af GABA-receptor
US5783575A (en) 1994-03-14 1998-07-21 Novo Nordisk A/S Antagonists, their preparation and use
US5696148A (en) 1994-03-14 1997-12-09 Novo Nordisk A/S Indole compounds and their use in treating diseases of the central nervous system
CZ265096A3 (en) 1994-03-14 1997-06-11 Novo Nordisk As Thienoindole derivatives, their use, process of their preparation and pharmaceutical composition containing thereof
US5637617A (en) 1994-04-01 1997-06-10 The Regents Of The University Of California Methods for use of GABAa receptor GABAergic compounds
GB9409705D0 (en) 1994-05-14 1994-07-06 Smithkline Beecham Plc Novel compounds
GB9410877D0 (en) 1994-05-31 1994-07-20 Bayer Ag Heterocyclycarbonyl substituted benzoduranyl-and-thiophenyl-alkanecarboxyclic acid derivatives
US6245774B1 (en) 1994-06-21 2001-06-12 Celltech Therapeutics Limited Tri-substituted phenyl or pyridine derivatives
US5786354A (en) 1994-06-21 1998-07-28 Celltech Therapeutics, Limited Tri-substituted phenyl derivatives and processes for their preparation
GB9412573D0 (en) 1994-06-22 1994-08-10 Celltech Ltd Chemical compounds
GB9412571D0 (en) 1994-06-22 1994-08-10 Celltech Ltd Chemical compounds
GB9412672D0 (en) 1994-06-23 1994-08-10 Celltech Ltd Chemical compounds
JP2852608B2 (ja) 1994-06-27 1999-02-03 雪印乳業株式会社 口腔乾燥症治療剤
US5750566A (en) 1994-08-12 1998-05-12 Eli Lilly And Company Synthetic excitatory amino acids
WO1996006843A1 (en) 1994-08-29 1996-03-07 Yamanouchi Pharmaceutical Co., Ltd. Novel naphthyridine derivative and medicinal composition thereof
WO1996010570A1 (en) 1994-09-30 1996-04-11 Pfizer Inc. NEUROLEPTIC 2,7-DISUBSTITUTED PERHYDRO-1H-PYRIDO[1,2-a]PYRAZINES
GB9420010D0 (en) 1994-10-01 1994-11-16 Marck Sharp & Dohme Limited Nucleic acids
US5554645A (en) 1994-10-03 1996-09-10 Mars, Incorporated Antineoplastic cocoa extracts and methods for making and using the same
DE4436509A1 (de) 1994-10-13 1996-04-18 Hoechst Schering Agrevo Gmbh Substituierte Spiroalkylamino- und alkoxy-Heterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Schädlingsbekämpfungsmittel und Fungizide
JP3993651B2 (ja) 1994-10-21 2007-10-17 アスビオファーマ株式会社 シクロプロパクロメンカルボン酸誘導体
US5473077A (en) 1994-11-14 1995-12-05 Eli Lilly And Company Pyrrolidinyl di-carboxylic acid derivatives as metabotropic glutamate receptor agonists
BR9509764A (pt) 1994-11-23 1998-07-07 Cocensys Inc Série androstano e pregnano para modulação alostérica de receptor de gaba
GB9423911D0 (en) 1994-11-26 1995-01-11 Pfizer Ltd Therapeutic agents
GB9423910D0 (en) 1994-11-26 1995-01-11 Pfizer Ltd Therapeutic agents
GB9503601D0 (en) 1995-02-23 1995-04-12 Merck Sharp & Dohme Method of treatment and method of manufacture of medicament
CA2189355A1 (en) 1995-03-01 1996-09-06 Yasuo Onoda Imidazoquinazoline derivatives
US5488055A (en) 1995-03-10 1996-01-30 Sanofi Winthrop Inc. Substituted N-cycloalkylmethyl-1H-pyrazolo(3,4-b)quinolin-4 amines and compositions and methods of use thereof
CA2218493C (en) * 1995-04-21 2005-02-22 Neurosearch A/S Benzimidazole compounds and their use as modulators of the gabaa receptor complex
JPH11504905A (ja) * 1995-05-05 1999-05-11 ノボ ノルディスク アクティーゼルスカブ 新規複素環の化学
DE19518082A1 (de) 1995-05-17 1996-11-21 Merck Patent Gmbh 4(-Arylaminomethylen)-2,4-dihydropyrazol-3-one
PT828728E (pt) 1995-05-18 2003-06-30 Altana Pharma Ag Di-hidrobenzofuranos de fenilo
ATE230404T1 (de) 1995-05-18 2003-01-15 Altana Pharma Ag Cyclohexyldihydrobenzofurane
US6514996B2 (en) 1995-05-19 2003-02-04 Kyowa Hakko Kogyo Co., Ltd. Derivatives of benzofuran or benzodioxole
US5637724A (en) * 1995-06-05 1997-06-10 Neurogen Corporation Substituted aryl and cycloalkyl imidazolones; a new class of GABA brain receptor ligands
US5637725A (en) 1995-06-05 1997-06-10 Neurogen Corporation Substituted aryl and cycloalkyl imidazolones; a new class of GABA brain receptor ligands
PT837874E (pt) * 1995-06-06 2005-03-31 Euro Celtique Sa Esteroides neuroactivos da serie androstano e pregnano
US5534522A (en) 1995-06-07 1996-07-09 Warner-Lambert Company (R)-(Z)-1-azabicyclo [2.2.1] heptan-3-one,O-[3-(3-methoxyphenyl)-2-propynyl] oxime maleate as a pharmaceutical agent
US5910590A (en) 1995-06-07 1999-06-08 Neurogen Corporation Certain aryl substituted pyrrolopyrazines; a new class of GABA brain receptor ligands
GB9514464D0 (en) 1995-07-14 1995-09-13 Glaxo Lab Sa Medicaments
EP0850215B1 (en) 1995-07-26 2000-10-18 Pfizer Inc. N-(aroyl)glycine hydroxamic acid derivatives and related compounds
US20010018074A1 (en) 1995-07-29 2001-08-30 Smithkline Beecham P.L.C. Process for preparing solid dosage forms of very low-dose drugs
AU6514196A (en) 1995-07-31 1997-02-26 Novo Nordisk A/S Heterocyclic compounds, their preparation and use
DE19533975A1 (de) 1995-09-14 1997-03-20 Merck Patent Gmbh Arylalkyl-diazinone
US6166041A (en) 1995-10-11 2000-12-26 Euro-Celtique, S.A. 2-heteroaryl and 2-heterocyclic benzoxazoles as PDE IV inhibitors for the treatment of asthma
AU706594B2 (en) 1995-11-06 1999-06-17 H. Lundbeck A/S Treatment of traumatic brain injury
US5800539A (en) 1995-11-08 1998-09-01 Emory University Method of allogeneic hematopoietic stem cell transplantation without graft failure or graft vs. host disease
ZA969485B (en) 1995-11-16 1998-05-12 Lilly Co Eli Excitatory amino acid receptor antagonists.
US5912248A (en) 1995-11-16 1999-06-15 Eli Lilly And Company Excitatory amino acid receptor antagonists
US5688826A (en) 1995-11-16 1997-11-18 Eli Lilly And Company Excitatory amino acid derivatives
IT1276153B1 (it) 1995-11-17 1997-10-27 Roberto Pellicciari Derivati di glicina ad attivita' antagonista dei recettori metabotropi del glutammato
GB9603723D0 (en) 1996-02-22 1996-04-24 Merck & Co Inc Diphenyl pyridyl derivatives as pde iv inhibitors
US5710170A (en) 1995-12-15 1998-01-20 Merck Frosst Canada, Inc. Tri-aryl ethane derivatives as PDE IV inhibitors
GB9526245D0 (en) 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Chemical compounds
GB9526246D0 (en) 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Chemical compounds
GB9526243D0 (en) 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Chemical compounds
US5804686A (en) * 1996-01-19 1998-09-08 Neurogen Corporation fused pyrrolecarboxamides; a new class of GABA brain receptor ligands
US6211365B1 (en) 1996-01-19 2001-04-03 Neurogen Corporation Fused pyrrolecarboxamides; a new class of GABA brain receptor ligands
EE03523B1 (et) 1996-01-31 2001-10-15 Byk Gulden Lomberg Chemische Fabrik Gmbh Fenantridiinid, neid sisaldavad ravimid ja nende kasutamine
GB9604926D0 (en) 1996-03-08 1996-05-08 Sandoz Ltd Organic compounds
US5792766A (en) 1996-03-13 1998-08-11 Neurogen Corporation Imidazo 1,5-c! quinazolines; a new class of GABA brain receptor ligands
WO1997034870A1 (en) * 1996-03-22 1997-09-25 Neurogen Corporation Certain fused pyrrolecarboxamides as gaba brain receptor ligands
US5677309A (en) 1996-03-22 1997-10-14 Neurogen Corporation 1,2,4-triazolo 4,3-c! quinazolin-3-ones and 1,2,4-triazolo 4,3-c!quinazolin-3-thiones; a new class of GABA brain receptor ligands
US6777217B1 (en) 1996-03-26 2004-08-17 President And Fellows Of Harvard College Histone deacetylases, and uses related thereto
US6127378A (en) 1996-03-26 2000-10-03 Byk Gulden Lomberg Chemische Fabrik Gmbh Phenanthridines substituted in the 6 position
FR2746800B1 (fr) 1996-03-29 1998-06-05 Jouveinal Inst Rech Diazepino-indoles inhibiteurs de phosphodiesterases 4
US6297273B1 (en) 1996-04-02 2001-10-02 Mars, Inc. Use of cocoa solids having high cocoa polyphenol content in tabletting compositions and capsule filling compositions
FR2754260B1 (fr) 1996-10-04 1998-10-30 Adir Nouveaux derives substitues de biphenyle ou de phenylpyridine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US5723462A (en) * 1996-04-26 1998-03-03 Neurogen Corporation Certain fused pyrrolecarboxamides a new class of GABA brain receptor ligands
AP2001002304A0 (en) 1996-05-03 2001-12-31 Pfizer Substituted indazole derivatives and related compounds
ATE215950T1 (de) 1996-05-10 2002-04-15 Icos Corp Carbolinderivate
NZ332341A (en) 1996-05-20 2000-05-26 Darwin Discovery Ltd Quinoline carboxamides as TNF inhibitors and as PDE-IV inhibitors
HUP0100042A3 (en) 1996-05-20 2003-01-28 Darwin Discovery Ltd Cambridge Benzofuran carboxamides medicaments containing the same and their therapeutic use
JP2000510866A (ja) 1996-05-20 2000-08-22 ダーウィン・ディスカバリー・リミテッド Tnfとpde―ivのインヒビターとしてのキノリンスルホンアミド
CA2258728C (en) 1996-06-19 2011-09-27 Rhone Poulenc Rorer Limited Substituted azabicylic compounds and their use as inhibitors of the production of tnf and cyclic amp phosphodiesterase
PL330974A1 (en) 1996-06-25 1999-06-21 Pfizer Substituted derivatives of indazole and their application as inhibitors of phosphodiesterase (pde) of iv type and of tumor necrosis factor (tnf)
US6017924A (en) 1996-06-27 2000-01-25 Ligand Pharmaceuticals Incorporated Androgen receptor modulator compounds and methods
EP0913389A4 (en) 1996-06-28 2000-02-02 Nippon Chemiphar Co CYCLOPROPYLGLYCINE DERIVATIVES AND AGONISTS OF THE L-GLUTAMATE RECEPTOR TYPE OF METABOLITE REGULATION
GB9614718D0 (en) 1996-07-12 1996-09-04 Bayer Ag 3-ureido-pyridofurans and -pyridothiophenes
DE19628621A1 (de) 1996-07-16 1998-01-22 Byk Gulden Lomberg Chem Fab Neue 4-substituierte Benzofurane
EP0915875B1 (en) 1996-07-25 2003-04-09 MERCK SHARP & DOHME LTD. Substituted triazolo-pyridazine derivatives as ligands for gaba receptors
US20020127271A1 (en) 1996-07-25 2002-09-12 Smithkline Beecham P.L.C. Formulation for the treatment and/or prophylaxis of dementia
EP0915877A1 (en) 1996-07-25 1999-05-19 MERCK SHARP & DOHME LTD. SUBSTITUTED TRIAZOLO PYRIDAZINE DERIVATIVES AS INVERSE AGONISTS OF THE GABA A?$g(a)5 RECEPTOR SUBTYPE
AU3967297A (en) 1996-08-01 1998-02-25 Cocensys, Inc. Use of gaba and nmda receptor ligands for the treatment of migraine headache
PT956865E (pt) 1996-08-12 2007-07-30 Mitsubishi Pharma Corp Medicamentos compreendendo inibidores da rho cinase.
DE19632549A1 (de) 1996-08-13 1998-02-19 Merck Patent Gmbh Arylalkanoylpyridazine
ES2188983T4 (es) 1996-08-19 2004-06-01 Altana Pharma Ag Nuevas benzofuran-4-carboxamidas.
ES2208950T3 (es) 1996-08-26 2004-06-16 Altana Pharma Ag Nuevos derivados de tiazol con un efecto inhibidor de fosfodiesterasas.
US6312753B1 (en) 1996-09-06 2001-11-06 Mars, Incorporated Cocoa components, edible products having enriched polyphenol content, methods of making same and medical uses
US6015913A (en) 1996-09-06 2000-01-18 Mars, Incorporated Method for producing fat and/or solids from cocoa beans
US20010003588A1 (en) 1996-09-12 2001-06-14 Smithkline Beecham Corporation Controlled release dosage form of [R-(Z)]-alpha-(methoxyimino)-alpha-(1-azabicyclo[2.2.2.]oct-3-yl)acetonitrile monohydrochloride
ATE236884T1 (de) 1996-10-02 2003-04-15 Janssen Pharmaceutica Nv Pde-iv hemmende 2-cyanoiminoimidazol-derivate
WO1998016528A1 (en) 1996-10-11 1998-04-23 Chiron Corporation Purine inhibitors of glycogen synthase kinase 3 (gsk3)
DE19642451A1 (de) 1996-10-15 1998-04-16 Merck Patent Gmbh Aminothiophencarbonsäureamide
GB9621789D0 (en) 1996-10-18 1996-12-11 Lilly Industries Ltd Pharmaceutical compounds
AU726447B2 (en) * 1996-10-21 2000-11-09 Neurosearch A/S 1-phenyl-benzimidazole compounds and their use as BAGA-A receptor modulators
GB9622386D0 (en) 1996-10-28 1997-01-08 Sandoz Ltd Organic compounds
US6331543B1 (en) 1996-11-01 2001-12-18 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
US6069151A (en) 1996-11-06 2000-05-30 Darwin Discovery, Ltd. Quinolines and their therapeutic use
DE69723863T2 (de) 1996-11-06 2004-04-15 Darwin Discovery Ltd., Slough Chinoline und deren therapeutische verwendung
JP2001504462A (ja) 1996-11-12 2001-04-03 ビイク グルデン ロンベルク ヒエーミツシエ フアブリーク ゲゼルシヤフト ミツト ベシユレンクテル ハフツング ホスホジエステラーゼ阻害剤としての(2,3―ジヒドロベンゾフラニル)―チアゾール
JP2001505198A (ja) 1996-11-20 2001-04-17 ビイク グルデン ロンベルク ヒエーミツシエ フアブリーク ゲゼルシヤフト ミツト ベシユレンクテル ハフツング Pde阻害剤としての置換ジヒドロベンゾフラン
GB9625184D0 (en) 1996-12-04 1997-01-22 Celltech Therapeutics Ltd Chemical compounds
SK283270B6 (sk) 1997-01-15 2003-04-01 Altana Pharma Ag Ftalazinóny, farmaceutické prostriedky s ich obsahom a ich použitie
GB9702524D0 (en) 1997-02-07 1997-03-26 Merck Sharp & Dohme Therapeutic agents
PT975347E (pt) 1997-02-28 2008-05-23 Nycomed Gmbh Combinação sinérgica de inibidores da pde e agonistas da adenilato ciclase ou agonistas da guanil ciclise
ES2131463B1 (es) 1997-04-08 2000-03-01 Lilly Sa Derivados de ciclopropilglicina con propiedades farmaceuticas.
GB9708945D0 (en) 1997-05-01 1997-06-25 Merck Sharp & Dohme Therapeutic agents
US6387673B1 (en) 1997-05-01 2002-05-14 The Salk Institute For Biological Studies Compounds useful for the modulation of processes mediated by nuclear hormone receptors, methods for the identification and use of such compounds
US6043252A (en) 1997-05-05 2000-03-28 Icos Corporation Carboline derivatives
WO1998050385A1 (en) 1997-05-08 1998-11-12 Merck Sharp & Dohme Limited SUBSTITUTED 1,2,4-TRIAZOLO[3,4-a]PHTHALAZINE DERIVATIVES AS GABA ALPHA 5 LIGANDS
ZA983930B (en) 1997-05-14 1999-11-08 Lilly Co Eli Excitatory amino acid receptor modulators.
DE69825605T2 (de) 1997-05-29 2005-09-15 H. Lundbeck A/S Behandlung der schizophrenie und der psychose
GB9713707D0 (en) 1997-06-27 1997-09-03 Merck Sharp & Dohme Therapeutic agents
US6825211B1 (en) 1997-07-18 2004-11-30 Georgetown University Bicyclic metabotropic glutamate receptor ligands
JP2001515839A (ja) 1997-07-18 2001-09-25 ジョージタウン・ユニバーシティ 二環式向代謝性グルタミン酸受容体リガンド
PT1000035E (pt) 1997-07-25 2003-04-30 Altana Pharma Ag 6-fenilfenantridinas substituidas
GB9715977D0 (en) 1997-07-29 1997-10-01 Merck Sharp & Dohme Therapeutic agents
ES2137113B1 (es) 1997-07-29 2000-09-16 Almirall Prodesfarma Sa Nuevos derivados de triazolo-piridazinas heterociclicos.
US6107295A (en) 1997-08-01 2000-08-22 Merck Patent Gesellschaft Mit Beschrankter Haftung Arylalkanoyl pyridazines
HUP0001054A3 (en) 1997-08-06 2001-01-29 Daiichi Asubio Pharma Co Ltd 1-aryl-1,8-naphthyridin-4-one derivative as type iv phosphodiesterase inhibitor
US6143760A (en) 1997-08-25 2000-11-07 Neurogen Corporation Substituted 4-oxo-napthyridine-3-carboxamides: GABA brain receptor ligands
US6207842B1 (en) 1997-10-09 2001-03-27 Mars Incorporated Process for preparing procyanidin(4-6 or 4-8) oligomers and their derivatives
GB9721437D0 (en) 1997-10-10 1997-12-10 Glaxo Group Ltd Heteroaromatic compounds and their use in medicine
US6156753A (en) 1997-10-28 2000-12-05 Vivus, Inc. Local administration of type III phosphodiesterase inhibitors for the treatment of erectile dysfunction
US6127363A (en) 1997-10-28 2000-10-03 Vivus, Inc. Local administration of Type IV phosphodiesterase inhibitors for the treatment of erectile dysfunction
UA64769C2 (uk) 1997-11-07 2004-03-15 Х. Луннбек А/С Гідрогалогеніди 1'-[4-[1-(4-фторофеніл)-1н-індол-3-іл]-1-бутил]-спіро[ізобензофуран-1(3н),4'-піперидину], фармацевтична композиція та спосіб лікування
HU227841B1 (en) 1997-11-12 2012-05-02 Bayer Pharma AG 2-phenyl substituted imidazotriazinones, process for their preparation and pharmaceutical compositions thereof
WO1999025353A1 (en) 1997-11-13 1999-05-27 Merck Sharp & Dohme Limited Therapeutic uses of triazolo-pyridazine derivatives
US6429207B1 (en) 1997-11-21 2002-08-06 Nps Pharmaceuticals, Inc. Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases
DE19882893T1 (de) 1997-12-12 2001-02-22 Euro Celtique Sa Herstellung von 3-substituierten Adeninen
IT1296985B1 (it) 1997-12-19 1999-08-03 Zambon Spa Derivati benzazinici inibitori della fosfodiesterasi 4
AU746866B2 (en) 1998-01-14 2002-05-02 Merck Sharp & Dohme Limited Triazolo-pyridazine derivatives as ligands for GABA receptors
GB9801208D0 (en) * 1998-01-21 1998-03-18 Merck Sharp & Dohme Therapeutic agents
GB9801210D0 (en) 1998-01-21 1998-03-18 Merck Sharp & Dohme Therapeutic agents
GB9801202D0 (en) 1998-01-21 1998-03-18 Merck Sharp & Dohme Therapeutic agents
GB9801234D0 (en) 1998-01-21 1998-03-18 Merck Sharp & Dohme Therapeutic agents
MXPA00007135A (es) 1998-01-21 2002-11-07 Merck Sharp & Dohme Derivados de triazolo-piridazina como ligandos para receptores gaba.
GB9801397D0 (en) 1998-01-22 1998-03-18 Merck Sharp & Dohme Therapeutic agents
CA2285352A1 (en) 1998-01-29 1999-08-05 Suntory Limited 1-cycloalkyl-1,8-naphthyridin-4-one derivatives with phosphodiesterase iv inhibitory activity
US6103903A (en) 1998-02-26 2000-08-15 Neurogen Corporation 4-(4-piperidylmethyhlamino) substituted heteroaryl fused pyridines: GABA brain receptor ligands
AU2794099A (en) 1998-02-26 1999-09-15 Neurogen Corporation Substituted cycloalkyl-4-oxonicotinic carboxamides; gaba brain receptor ligands
AU2793199A (en) 1998-02-26 1999-09-15 Neurogen Corporation 2-(het-)aryl-4-(cyclic amino substituted) heteroaryl fused pyridine derivatives,their preparation and their use as (ant-)agonists for gaba (a) brain receptors
AU2881199A (en) 1998-02-26 1999-09-15 Neurogen Corporation Substituted 1,4-dihydro-4-oxonicotinic carboxamides: gaba brain receptor ligands
US6900228B1 (en) 1998-03-10 2005-05-31 Research Triangle Institute Opiate compounds, methods of making and methods of use
US6805883B2 (en) 1998-03-12 2004-10-19 Mars, Incorporated Food products containing polyphenol(s) and L-arginine to stimulate nitric oxide
AU758241B2 (en) 1998-03-13 2003-03-20 University Of British Columbia, The Granulatimide derivatives for use in cancer treatment
GB9806102D0 (en) 1998-03-20 1998-05-20 Merck Sharp & Dohme Therapeutic agents
FR2776660B1 (fr) 1998-03-27 2000-05-12 Parke Davis Diazepino-indoles de phosphodiesterases iv
EP1071655A1 (en) 1998-04-17 2001-01-31 Kenneth Curry Cubane derivatives as metabotropic glutamate receptor antagonists and process for their preparation
ES2203078T3 (es) 1998-04-20 2004-04-01 Pfizer Inc. Parazolopirimidinonas inhibidoras de gmpc pde5 para el tratamiento de la disfuncion sexual.
DK1076657T3 (da) 1998-04-28 2004-11-08 Elbion Ag Hidtil ukendte hydroxyindoler, deres anvendelse som inhibitorer for phosphodiesterase 4 og fremgangsmåde til deres fremstilling
CA2330738A1 (en) 1998-05-05 1999-11-11 Byk Gulden Lomberg Chemische Fabrik Gmbh Novel n-oxides of benzonaphthyridines
WO1999059409A1 (en) 1998-05-21 1999-11-25 Matsumoto Rae R Compounds and uses thereof
US6362371B1 (en) * 1998-06-08 2002-03-26 Advanced Medicine, Inc. β2- adrenergic receptor agonists
US6897305B2 (en) 1998-06-08 2005-05-24 Theravance, Inc. Calcium channel drugs and uses
AU757198B2 (en) 1998-06-10 2003-02-06 Altana Pharma Ag Benzamides with tetrahydrofuranyloxy substitutents as phosphodiesterase 4 inhibitors
US6479506B1 (en) 1998-06-16 2002-11-12 Merck Sharp & Dohme Ltd. Triazolo-pyridine derivatives as ligands for GABA receptors
GB9813006D0 (en) * 1998-06-16 1998-08-12 Merck Sharp & Dohme Therapeutic agents
DE19826841A1 (de) 1998-06-16 1999-12-23 Merck Patent Gmbh Arylalkanoylpyridazine
DE69919707T2 (de) 1998-06-19 2005-09-01 Chiron Corp., Emeryville Glycogen synthase kinase 3 inhibitoren
AUPP438498A0 (en) * 1998-06-29 1998-07-23 Garvan Institute Of Medical Research Novel Gaba-B receptor
DE69916066T2 (de) 1998-07-06 2005-02-24 Altana Pharma Ag Neue benzoxazole mit pde-hemmender wirkung
ITMI981671A1 (it) 1998-07-21 2000-01-21 Zambon Spa Derivati ftalazinici inibitori della fosfodisterasi 4
US6177569B1 (en) 1998-08-25 2001-01-23 Neurogen Corporation Oxo-pyridoimidazole-carboxamides: GABA brain receptor ligands
EP1107738A4 (en) 1998-08-27 2003-01-22 Bristol Myers Squibb Co Novel pharmaceutical salt form
DE69918136T2 (de) 1998-08-31 2005-07-07 Taisho Pharmaceutical Co., Ltd. 6-Fluorobicyclo[3.1.0]Hexan-Derivate
BR9913405A (pt) 1998-09-03 2001-10-02 Kyowa Hakko Kogyo Kk Composto heterocìclico que contenha oxigênio, e, inibidor de fosfodiesterase (pde) iv.
CH694053A5 (de) 1998-09-03 2004-06-30 Hoffmann La Roche Verfahren zur Herstellung von 2-Amino-bicyclo[3.1.0]hexan-2,6-dicarbonsäure-Derivaten.
WO2000015639A1 (en) 1998-09-16 2000-03-23 Icos Corporation Carboline derivatives as cgmp phosphodiesterase inhibitors
WO2000017184A1 (en) 1998-09-24 2000-03-30 Mitsubishi Chemical Corporation Hydroxyflavone derivatives as tau protein kinase 1 inhibitors
AR023052A1 (es) 1998-09-25 2002-09-04 Mitsuharu Yoshimura Milton Derivados de pirimidona
JP2002527419A (ja) 1998-10-08 2002-08-27 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー Gsk−3阻害物質としてのピロール−2,5−ジオン類
US6719520B2 (en) 1998-10-08 2004-04-13 Smithkline Beecham Corporation Method and compounds
DE69936998T2 (de) 1998-10-16 2008-05-21 Merck Sharp & Dohme Ltd., Hoddesdon Pyrazolotriazinderivate als gaba-rezeptorliganden
DE19850701A1 (de) 1998-11-04 2000-05-11 Merck Patent Gmbh Benzoylpyridazine
CA2349700A1 (en) 1998-11-12 2000-05-18 Merck & Co., Inc. Therapeutic polymorphs of a gaba-a alpha-5 inverse agonist and pamoate formulations of the same
PE20001236A1 (es) 1998-11-13 2000-11-10 Lilly Co Eli Moduladores del receptor de aminoacidos excitadores
SE9804064D0 (sv) 1998-11-25 1998-11-25 A & Science Invest Ab Medicinal product and method for treatment of conditions affecting neural stem cells or progenitor cells
US6130333A (en) 1998-11-27 2000-10-10 Monsanto Company Bicyclic imidazolyl derivatives as phosphodiesterase inhibitors, pharmaceutical compositions and method of use
US6414147B1 (en) 1998-12-23 2002-07-02 Neurogen Corporation 2-amino-9-alkylpurines: GABA brain receptor ligands
GB9828640D0 (en) 1998-12-23 1999-02-17 Smithkline Beecham Plc Novel method and compounds
JP2002535407A (ja) 1999-01-27 2002-10-22 メルク シャープ エンド ドーム リミテッド Gaba受容体のリガンドとしてのトリアゾロピリダジン誘導体
US6342496B1 (en) 1999-03-01 2002-01-29 Sepracor Inc. Bupropion metabolites and methods of use
US6498176B1 (en) 1999-03-04 2002-12-24 Smithklinebeecham Corporation 3-(anilinomethylene) oxindoles as protein tyrosine kinase and protein serine/threonine kinase inhibitors
TW575561B (en) 1999-03-25 2004-02-11 Hoffmann La Roche 1-arenesulfonyl-2-aryl-pyrrolidine and piperidine derivatives
DE19915365A1 (de) 1999-04-06 2000-10-12 Merck Patent Gmbh Tetrahydropyridazin-Derivate
JP5095050B2 (ja) 1999-04-28 2012-12-12 ジョージタウン ユニバーシティー 代謝調節型グルタミン酸受容体のリガンド、及び、NAALADaseの阻害剤
US6528499B1 (en) 2000-04-27 2003-03-04 Georgetown University Ligands for metabotropic glutamate receptors and inhibitors of NAALADase
FR2792938B1 (fr) 1999-04-28 2001-07-06 Warner Lambert Co NOUVELLES 1-AMINO TRIAZOLO [4,3-a] QUINAZOLINE-5-ONES INHIBITRICES DE PHOSPHODIESTERASES IV
US6943166B1 (en) 1999-04-30 2005-09-13 Lilly Icos Llc. Compositions comprising phosphodiesterase inhabitors for the treatment of sexual disfunction
US6737242B1 (en) * 1999-05-07 2004-05-18 Neurogen Corporation Methods for screening GABA-modulatory compounds for specified pharmacological activities
US6316472B1 (en) 1999-05-13 2001-11-13 Merck Frosst Canada & Co. Heterosubstituted pyridine derivatives as PDE 4 inhibitors
US6448246B1 (en) 1999-05-25 2002-09-10 Neurogen Corporation Substituted 4H-1,4-benzothiazine-2-carboxamide: GABA brain receptor ligands
US6498180B1 (en) 1999-06-03 2002-12-24 Eli Lilly And Company Excitatory amino acid receptor modulators
US6906177B1 (en) 1999-06-10 2005-06-14 Takeda Chemical Industries, Ltd. GABA transporter protein and DNA thereof
US6146876A (en) 1999-06-11 2000-11-14 Millennium Pharmaceuticals, Inc. 22025, a novel human cyclic nucleotide phosphodiesterase
US6297256B1 (en) 1999-06-15 2001-10-02 Neurogen Corporation Aryl and heteroaryl substituted pyridino derivatives GABA brain receptor ligands
DE19928146A1 (de) 1999-06-19 2000-12-21 Merck Patent Gmbh Thienopyrimidine
FR2795724B1 (fr) 1999-07-02 2002-12-13 Sanofi Synthelabo Nouveaux derives du benzene, un procede pour leur preparation et les compositions pharmaceutiques les contenant
TR200200161T2 (tr) 1999-07-21 2002-05-21 Fujisawa Pharmaceutical Co. Ltd. Benzimidazol türevleri ve onların fosfodiesteraz olarak kullanımı.
GB9918180D0 (en) 1999-08-02 1999-10-06 Smithkline Beecham Plc Novel compositions
US6821975B1 (en) 1999-08-03 2004-11-23 Lilly Icos Llc Beta-carboline drug products
US20050137206A1 (en) 1999-08-05 2005-06-23 Yevich Joseph P. Method for treatment of anxiety and depression
ES2209728T3 (es) 1999-08-06 2004-07-01 F. Hoffmann-La Roche Ag Tetrahidro-benzo(d)azepinas y su uso como antagonistas de receptores de glutamato metabotropico.
US6476019B1 (en) 1999-08-13 2002-11-05 Sepracor Inc. Spirocyclic ligands for sigma receptors, and libraries and methods of use thereof
US6660753B2 (en) 1999-08-19 2003-12-09 Nps Pharmaceuticals, Inc. Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
EP1210118B1 (en) * 1999-08-20 2004-12-08 Ortho-McNeil Pharmaceutical, Inc. Composition comprising a tramadol material and an anticonvulsant drug
US6313159B1 (en) 1999-08-20 2001-11-06 Guilford Pharmaceuticals Inc. Metabotropic glutamate receptor ligand derivatives as naaladase inhibitors
GB9919957D0 (en) 1999-08-23 1999-10-27 Merck Sharp & Dohme Therapeutic agents
US6566372B1 (en) 1999-08-27 2003-05-20 Ligand Pharmaceuticals Incorporated Bicyclic androgen and progesterone receptor modulator compounds and methods
EP1212322A2 (en) 1999-08-27 2002-06-12 Ligand Pharmaceuticals Incorporated 8-substituted-6-trifluoromethyl-9-pyrido[3,2-g]quinoline compounds as androgen receptor modulators
MXPA02002032A (es) 1999-08-27 2003-05-19 Ligand Pharm Inc Compuestos moduladores del receptor de androgeno y metodos.
US6956049B1 (en) 1999-08-31 2005-10-18 Merck & Co., Inc. Methods of modulating processes mediated by excitatory amino acid receptors
US20050014939A1 (en) * 1999-08-31 2005-01-20 Neurogen Corporation Fused pyrrolecarboxamides: GABA brain receptor ligands
GB9921150D0 (en) * 1999-09-07 1999-11-10 Merck Sharp & Dohme Therapeutic agents
GB9921351D0 (en) 1999-09-09 1999-11-10 Merck Sharp & Dohme Therapeutic agents
CA2383466C (en) 1999-09-16 2009-08-25 Tanabe Seiyaku Co., Ltd. Aromatic nitrogen-containing 6-membered cyclic compounds
TWI265925B (en) 1999-10-11 2006-11-11 Pfizer Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them
US6552016B1 (en) 1999-10-14 2003-04-22 Curis, Inc. Mediators of hedgehog signaling pathways, compositions and uses related thereto
AU779874B2 (en) 1999-10-15 2005-02-17 F. Hoffmann-La Roche Ag Benzodiazepine derivatives
US7491742B2 (en) 1999-10-21 2009-02-17 Merck Patent Gmbh Imidazole derivatives as phosphodiesterase VII inhibitors
AR029185A1 (es) 1999-10-25 2003-06-18 Yamanouchi Pharma Co Ltd Derivado de naftiridina
US6534287B1 (en) 1999-10-25 2003-03-18 Nps Pharmaceuticals, Inc. Human metabotropic glutamate receptor
DE19953025A1 (de) 1999-11-04 2001-05-10 Merck Patent Gmbh Pyrrolderivate als Phosphodiesterase VII-Hemmer
DE19953414A1 (de) 1999-11-06 2001-05-10 Merck Patent Gmbh Imidazopyridinderivate als Phospodiesterase VII-Hemmer
DE19954707A1 (de) 1999-11-13 2001-05-17 Merck Patent Gmbh Imidazolverbindungen als Phosphodiesterase VII-Hemmer
DE19955408A1 (de) * 1999-11-18 2001-05-23 Bayer Ag GABA-B-Rezeptoren
FR2801216A1 (fr) 1999-11-23 2001-05-25 Centre Nat Rech Scient Utilisation de derives d'indirubine pour la fabrication de medicaments
KR20100035666A (ko) 1999-11-23 2010-04-05 메틸진 인크. 히스톤 디아세틸라제의 억제제
GB9927687D0 (en) * 1999-11-23 2000-01-19 Merck Sharp & Dohme Therapeutic agents
DE69912808T2 (de) 1999-12-08 2004-09-30 Centre National De La Recherche Scientifique (C.N.R.S.) Verwendung von Hymenialdisin und dessen Derivaten zur Herstellung therapeutischer Mittel
ATE261445T1 (de) 1999-12-08 2004-03-15 Grelan Pharmaceutical Co Neue 1,8-naphtyridin-2(1h)-on-derivate
AU1734401A (en) 1999-12-09 2001-06-18 Mitsubishi Pharma Corporation Carboxyamido derivatives
US6376489B1 (en) 1999-12-23 2002-04-23 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
GB9929685D0 (en) 1999-12-15 2000-02-09 Merck Sharp & Dohme Therapeutic agents
US6680336B2 (en) 1999-12-15 2004-01-20 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
GB9929687D0 (en) * 1999-12-15 2000-02-09 Merck Sharp & Dohme Therapeutic agents
ES2246927T3 (es) 1999-12-17 2006-03-01 Chiron Corporation Inhibidores biciclicos de glucogeno sintasa quinasa 3.
CN1272328C (zh) 1999-12-17 2006-08-30 希龙公司 糖元合成酶激酶3的基于吡嗪的抑制剂
US6372777B1 (en) 1999-12-23 2002-04-16 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
US6313156B1 (en) 1999-12-23 2001-11-06 Icos Corporation Thiazole compounds as cyclic-AMP-specific phosphodiesterase inhibitors
US6294561B1 (en) 1999-12-23 2001-09-25 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
US6362213B1 (en) 1999-12-23 2002-03-26 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
US6258833B1 (en) 1999-12-23 2001-07-10 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
US6348602B1 (en) 1999-12-23 2002-02-19 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
US6569885B1 (en) 1999-12-23 2003-05-27 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
GB0000564D0 (en) * 2000-01-11 2000-03-01 Merck Sharp & Dohme Therapeutic agents
US6586582B2 (en) 2000-01-18 2003-07-01 Lexicon Genetics Incorporated Human GABA receptor proteins and polynucleotides encoding the same
CZ20022413A3 (cs) 2000-01-31 2003-08-13 Pfizer Products Inc. Pyrimidinkarboxamidy užitečné jako inhibitory isozymů PDE4
JP2003523741A (ja) 2000-02-01 2003-08-12 ヒューマン ジノーム サイエンシーズ, インコーポレイテッド Bcl−2様ポリヌクレオチド、ポリペプチドおよび抗体
AU2001234420A1 (en) 2000-02-03 2001-08-14 Eli Lilly And Company Potentiators of glutamate receptors
US20010039275A1 (en) 2000-02-04 2001-11-08 Bowler Andrew Neil Use of 2,4-diaminothiazole derivatives
WO2001056567A1 (en) 2000-02-04 2001-08-09 Novo Nordisk A/S 2,4-diaminothiazole derivatives and their use as glycogen synthase kinase-3 (gsk-3) inhibitors
GB0003254D0 (en) 2000-02-11 2000-04-05 Darwin Discovery Ltd Heterocyclic compounds and their therapeutic use
FR2804959B1 (fr) 2000-02-15 2006-04-28 Centre Nat Rech Scient Utilisation de derives de paullones pour la fabrication de medicaments
NZ521576A (en) 2000-02-29 2005-06-24 Mitsubishi Pharma Corp Novel cyclic amide derivatives
GB0005700D0 (en) 2000-03-09 2000-05-03 Glaxo Group Ltd Therapy
AU2001239550A1 (en) 2000-03-23 2001-10-03 Takeda Chemical Industries Ltd. Furoisoquinoline derivatives, process for producing the same and use thereof
JP2005289808A (ja) 2000-03-23 2005-10-20 Sanofi-Aventis 3−置換−4−ピリミドン誘導体
EP1136482A1 (en) 2000-03-23 2001-09-26 Sanofi-Synthelabo 2-Amino-3-(alkyl)-pyrimidone derivatives as GSK3beta inhibitors
WO2001070243A2 (en) 2000-03-23 2001-09-27 Nexell Therapeutics Inc. A method for treating early breast cancer
EP1136485A1 (en) 2000-03-23 2001-09-26 Sanofi-Synthelabo Aminophenyl pyrimidone derivatives
AU2001262150A1 (en) 2000-03-23 2001-10-03 Mitsubishi Pharma Corporation 2-(nitrogen-heterocyclic)pyrimidone derivatives
WO2001070727A1 (en) 2000-03-23 2001-09-27 Sanofi-Synthelabo 2-(arylalkylamino)pyrimidone derivatives and 2-(heteroarylalkylamino)pyrimidone derivatives
JP2003528074A (ja) 2000-03-24 2003-09-24 メチルジーン インコーポレイテッド ヒストン脱アセチル化酵素の阻害剤
GB0007193D0 (en) 2000-03-25 2000-05-17 Univ Manchester Treatment of movrmrnt disorders
US6683192B2 (en) 2000-03-30 2004-01-27 Curis, Inc. Small organic molecule regulators of cell proliferation
GB0007842D0 (en) 2000-03-31 2000-05-17 Spruce Barbara Sigma receptor ligands and their medical uses
GB0008264D0 (en) 2000-04-04 2000-05-24 Smithkline Beecham Plc Novel method and compounds
GB0008696D0 (en) * 2000-04-07 2000-05-31 Merck Sharp & Dohme Therapeutic agents
WO2001076507A2 (en) 2000-04-11 2001-10-18 The University Of Miami Use of oxygen carriers to improve grafted cell survival in neural transplantation
KR20030005280A (ko) 2000-04-14 2003-01-17 마아즈, 인코오포레이티드 혈관의 건강을 개선하기 위한 조성물과 방법
CA2306170A1 (en) 2000-04-18 2001-10-18 Kenneth Curry Novel amino, carboxy derivatives of barbituric acid
WO2001081345A1 (en) 2000-04-20 2001-11-01 Mitsubishi Pharma Corporation Aromatic amide compounds
MXPA02011053A (es) 2000-05-11 2004-08-19 Kenneth Curry Compuestos novedosos de carboxi amino espiro (2,4)heptano y derivados de los mismos.
DE60129222T2 (de) 2000-05-11 2008-03-06 Consejo Superior de Investigaciónes Científicas Heterocyclischen inhibitoren von glycogen synthase kinase gsk-3
UA72611C2 (uk) 2000-05-17 2005-03-15 Орто-Макнейл Фармацевтикал, Інк. Похідні заміщеного піролопіридинону, корисні як інгібітори фосфодіестерази
UA74826C2 (en) 2000-05-17 2006-02-15 Ortho Mcneil Pharm Inc ?-carboline derivatives as phosphodiesterase inhibitors
WO2001089583A2 (en) 2000-05-23 2001-11-29 Neurologix, Inc. Glutamic acid decarboxylase (gad)_delivery system for treating neurodegenerative diseases
WO2001090108A1 (en) 2000-05-24 2001-11-29 Merck Sharp & Dohme Limited 3-phenyl-imidazo-pyrimidine derivatives as ligands for gaba receptors
AU781526B2 (en) 2000-05-30 2005-05-26 Societe Des Produits Nestle S.A. Primary composition containing a lipophilic bioactive compound
US7081481B2 (en) 2000-05-31 2006-07-25 Eli Lilly And Company Excitatory amino acid receptor modulators
CA2411013A1 (en) 2000-06-07 2001-12-13 Jose Manuel Prieto Soto 6-phenylpyrrolopyrimidinedione derivatives
EP1294721B1 (en) 2000-06-23 2006-07-19 Lilly Icos LLC Cyclic gmp-specific phosphodiesterase inhibitors
US6589978B2 (en) 2000-06-30 2003-07-08 Hoffman-La Roche Inc. 1-sulfonyl pyrrolidine derivatives
US6399641B1 (en) 2000-07-13 2002-06-04 Hoffmann-La Roche Inc. 2H-tetrazole-amide compounds with therapeutic activity as metabotropic glutamate receptor agonists
GB0018473D0 (en) 2000-07-27 2000-09-13 Merck Sharp & Dohme Therapeutic agents
CA2417277A1 (en) 2000-07-27 2002-02-07 F. Hoffmann-La Roche Ag 3-indolyl-4-phenyl-1h-pyrrole-2,5-dione derivatives as inhibitors of glycogen synthase kinase-3.beta.
GT200100147A (es) 2000-07-31 2002-06-25 Derivados de imidazol
EP1307201B1 (de) 2000-08-01 2004-11-24 Bayer HealthCare AG Selektive pde 2-inhibitoren als arzneimittel zur verbesserung der wahrnehmung
US6645990B2 (en) 2000-08-15 2003-11-11 Amgen Inc. Thiazolyl urea compounds and methods of uses
IL154425A0 (en) 2000-08-24 2003-09-17 Univ Tennessee Res H Corp Selective androgen receptor modulators and methods of use thereof
DZ3398A1 (fr) 2000-08-31 2002-03-07 Pfizer Prod Inc Derives pyrazole et leur utilisation comme inhibiteurs des proteines kinases
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
DE60103909T2 (de) 2000-09-01 2005-09-22 Sanofi-Aventis 2-pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-on- und 7-pyridinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5 1honderivate
EP1184384A1 (en) 2000-09-01 2002-03-06 Sanofi-Synthelabo 1-(Alkyl), 1-((heteroaryl)alkyl) and 1-((aryl)alkyl)-7-pyridin-4-ylimidazo(1,2a)pyrimidin-5(1H)-one derivatives
US6576644B2 (en) 2000-09-06 2003-06-10 Bristol-Myers Squibb Co. Quinoline inhibitors of cGMP phosphodiesterase
WO2002020495A2 (en) 2000-09-06 2002-03-14 Chiron Corporation Inhibitors of glycogen synthase kinase 3
WO2002022579A2 (en) 2000-09-11 2002-03-21 Sepracor, Inc. Antipsychotic sulfonamide-heterocycles, and methods of use thereof
US6613776B2 (en) 2000-09-15 2003-09-02 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
AU2001290912A1 (en) 2000-09-15 2002-03-26 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6610677B2 (en) 2000-09-15 2003-08-26 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
BR0114080A (pt) 2000-09-22 2003-07-29 Mars Uk Ltd Suplemento alimentìcio, uso do mesmo, método para auxiliar a prevenção ou tratamento de dano oxidativo, alimento, e, métodos para fabricar o mesmo, e para melhorar ou aumentar a produção de trabalho de um animal
CA2423868C (en) 2000-09-29 2011-06-07 Prolifix Limited Carbamic acid compounds comprising an amide linkage as hdac inhibitors
GB0023983D0 (en) 2000-09-29 2000-11-15 Prolifix Ltd Therapeutic compounds
EP2292593A3 (en) 2000-09-29 2011-05-25 TopoTarget UK Limited Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors
JP3830746B2 (ja) 2000-09-29 2006-10-11 スガツネ工業株式会社 ヒンジ装置
CN1703403A (zh) 2000-10-02 2005-11-30 詹森药业有限公司 趋代谢的谷氨酸盐受体拮抗剂
EP1193261A1 (en) 2000-10-02 2002-04-03 Warner-Lambert Company New thiadiazoles and their use as phosphodiesterase-7 inhibitors
WO2002032896A1 (en) 2000-10-16 2002-04-25 Novo Nordisk A/S Furazanyl-triazole derivates for the treatment of diseases
US20020103192A1 (en) 2000-10-26 2002-08-01 Curtin Michael L. Inhibitors of histone deacetylase
AU1253002A (en) 2000-11-10 2002-05-21 Merck Sharp & Dohme Imidazo-triazine derivatives as ligands for gaba receptors
GB0027561D0 (en) 2000-11-10 2000-12-27 Merck Sharp & Dohme Therapeutic agents
GB0117277D0 (en) 2001-07-16 2001-09-05 Merck Sharp & Dohme Therapeutic agents
NZ525147A (en) 2000-11-14 2004-10-29 Altana Pharma Ag (Dihydro)isoquinoline derivatives as phosphodiesterase inhibitors
TWI239333B (en) 2000-11-16 2005-09-11 Hoffmann La Roche Benzodiazepine derivatives as GABA A receptor modulators
AP2001002359A0 (en) * 2000-11-30 2001-12-31 Pfizer Prod Inc Combination of gaba agonists and aldose reductase inhibitors.
AR035659A1 (es) 2000-12-07 2004-06-23 Hoffmann La Roche Hidroxiamidas de acido (1-oxo-1,2,3,4-tetrahidro-naftalen-2-il)-alcanoico, proceso para la manufactura de estos compuestos, composiciones farmaceuticas que contienen dichos compuestos y los usos de los mismos
US6930114B2 (en) 2000-12-13 2005-08-16 Bayer Pharmaceuticals Corporation Pyrrolo (2.1a)dihydroisoquinolines and their use as phosphodiesterase 10a inhibitors
US6900215B2 (en) * 2000-12-15 2005-05-31 Merck Sharp & Dohme Ltd. Imidazo-pyrimidine derivatives as ligands for gaba receptors
US6562995B1 (en) 2000-12-21 2003-05-13 Beacon Laboratories, Inc. Delta dicarbonyl compounds and methods for using the same
BR0116493A (pt) 2000-12-21 2003-09-30 Vertex Pharma Compostos de pirazol úteis como inibidores de proteìna cinase
US6720445B2 (en) 2000-12-21 2004-04-13 Beacon Laboratories, Inc. Acetyloxymethyl esters and methods for using the same
ATE297734T1 (de) 2000-12-22 2005-07-15 Hoffmann La Roche Tetrahydro-(benzo- oder thieno-)azepin-pyrazin und triazinderivative als mglur 1 antagonisten
AR035513A1 (es) 2000-12-23 2004-06-02 Hoffmann La Roche Derivados de tetrahidropiridina, proceso para prepararlos, composiciones farmaceuticas que los contienen, y uso de dichos compuestos en la preparacion de medicamentos
GR1003861B (el) 2000-12-29 2002-04-11 Νεα νευροστεροειδη που αλληλεπιδρουν με τον υποδοχεα gabaa.
US6974824B2 (en) 2001-01-08 2005-12-13 Research Triangle Institute Kappa opioid receptor ligands
AR035417A1 (es) 2001-01-27 2004-05-26 Hoffmann La Roche Derivados triciclicos de lactama y sultama, procesos para su elaboracion, medicamentos que los contienen, y el uso de dichos compuestos en la preparacion de medicamentos
CZ20031903A3 (cs) 2001-01-31 2004-07-14 Pfizer Products Inc. Amidové deriváty thiazolyl-, oxazolyl-, pyrrolyl- a imidazolyl karboxylových kyselin užitečné jako inhibitory isozymů PDE4
KR20030070150A (ko) 2001-01-31 2003-08-27 화이자 프로덕츠 인크. Pde4 이소자임 억제제로서 유용한 에테르 유도체
WO2002060875A1 (en) 2001-01-31 2002-08-08 Pfizer Products Inc. Nicotinamide biaryl derivatives useful as inhibitors of pde4 isozymes
US6559159B2 (en) 2001-02-01 2003-05-06 Research Triangle Institute Kappa opioid receptor ligands
US20040176359A1 (en) * 2001-02-20 2004-09-09 University Of Kentucky Research Foundation Intranasal Benzodiazepine compositions
US6617357B2 (en) 2001-03-06 2003-09-09 Smithkline Beecham Corporation Compounds and their use as PDE inhibitors
US20020177594A1 (en) 2001-03-14 2002-11-28 Curtin Michael L. Inhibitors of histone deacetylase
WO2002076953A1 (en) 2001-03-21 2002-10-03 Warner-Lambert Company Llc New spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors
US6900329B2 (en) 2001-03-21 2005-05-31 Schering Corporation MCH antagonists and their use in the treatment of obesity
WO2002088079A2 (en) 2001-05-01 2002-11-07 Bristol-Myers Squibb Company Dual inhibitors of pde 7 and pde 4
GB0111191D0 (en) 2001-05-08 2001-06-27 Merck Sharp & Dohme Therapeutic agents
WO2002089782A2 (en) 2001-05-09 2002-11-14 President And Fellows Of Harvard College Dioxanes and uses thereof
PA8546001A1 (es) 2001-05-25 2003-12-30 Pfizer Un inhibidor de pde4 y un agente anticolinergico en combinacion para tratar enfermedades obstructivas de vias respiratorias
WO2002096423A2 (en) 2001-05-25 2002-12-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Combination of a pde4 inhibitor and tiotropium or derivate thereof for treating obstructive airways
MXPA03010961A (es) 2001-05-31 2004-02-27 Vertex Pharma Compuestos de tiazol utiles como inhibidores de proteinas cinasas.
WO2002100848A1 (en) 2001-06-12 2002-12-19 Sk Corporation Novel phenylalkyl diamine and amide analogs
AU2002315337A1 (en) * 2001-06-18 2003-01-02 Psychiatric Genomics, Inc. Method for neural stem cell differentiation using valproate
PE20030008A1 (es) 2001-06-19 2003-01-22 Bristol Myers Squibb Co Inhibidores duales de pde 7 y pde 4
CA2450934A1 (en) 2001-06-19 2002-12-27 Marco Dodier Pyrimidine inhibitors of phosphodiesterase (pde) 7
DE10130167A1 (de) 2001-06-22 2003-01-02 Bayer Ag Imidazotriazine
SE0102440D0 (sv) 2001-07-05 2001-07-05 Astrazeneca Ab New compound
GB0117060D0 (en) 2001-07-12 2001-09-05 Merck Sharp & Dohme Therapeutic agents
JP2003029331A (ja) 2001-07-13 2003-01-29 Sano Fuji Koki Co Ltd 反射型液晶プロジェクタ
WO2003010161A1 (en) 2001-07-24 2003-02-06 Bristol-Myers Squibb Company S-6-hydroxy-buspirone
EP1417188A1 (en) 2001-08-03 2004-05-12 Novo Nordisk A/S Novel 2,4-diaminothiazole derivatives
EP1285922A1 (en) 2001-08-13 2003-02-26 Warner-Lambert Company 1-Alkyl or 1-cycloalkyltriazolo[4,3-a]quinazolin-5-ones as phosphodiesterase inhibitors
JO2311B1 (en) 2001-08-29 2005-09-12 ميرك فروست كندا ليمتد Alkyl inhibitors Ariel phosphodiesterase-4
CA2465978C (en) 2001-09-14 2015-04-07 Soon Hyung Woo Inhibitors of histone deacetylase
US6897220B2 (en) 2001-09-14 2005-05-24 Methylgene, Inc. Inhibitors of histone deacetylase
EP1295884A1 (en) 2001-09-21 2003-03-26 Sanofi-Synthelabo 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a]Pyrimidin-4-one and 7-Pyrimidinyl-2,3-Dihydroimidazo[1,2-a]Pyrimidin-5(1H)one derivatives
BR0212896A (pt) 2001-09-21 2004-10-13 Sanofi Synthelabo Derivados de 2-piridinil-6,7,8,9-tetrahidropirimido[1,2-a]pirimidin-4- ona e 7-piridinil-2,3dihidroimidazo[1,2-a] pirimidin-5(1h)ona substituìdos
EP1295885A1 (en) 2001-09-21 2003-03-26 Sanofi-Synthelabo Substituted 2-pyridinyl-6,7,8,9-tetrahydropyrimido(1,2-a)pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo(1,2-a)pyrimidin-5(1H)one derivatives
WO2003027115A1 (en) 2001-09-21 2003-04-03 Sanofi-Synthelabo Substituted 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyrimidinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1h)one derivatives for neurodegenerative disorders
DE10148618B4 (de) 2001-09-25 2007-05-03 Schering Ag Substituierte N-(1,4,5,6-Tetrahydro-cyclopentapyrazol-3-yl)-Derivate, deren Herstellung und Verwendung als Arzneimittel
BR0212829A (pt) 2001-09-26 2004-08-03 Bayer Pharmaceuticals Corp Derivados de 1,8-naftiridina e seu uso para tratar diabetes e distúrbios relacionados
WO2004089942A2 (en) 2001-10-02 2004-10-21 Acadia Pharmaceuticals Inc. Benzimidazolidinone derivatives as muscarinic agents
US6951849B2 (en) 2001-10-02 2005-10-04 Acadia Pharmaceuticals Inc. Benzimidazolidinone derivatives as muscarinic agents
RU2288919C2 (ru) 2001-10-02 2006-12-10 Акадиа Фармасьютикалз, Инк. Производные бензимидазолидинона в качестве агентов мускариновых рецепторов
US6924311B2 (en) 2001-10-17 2005-08-02 X-Ceptor Therapeutics, Inc. Methods for affecting various diseases utilizing LXR compounds
AU2002337956B2 (en) 2001-10-25 2006-02-23 Schering Corporation MCH Antagonists for the treatment of obesity
IL161662A0 (en) 2001-11-01 2004-09-27 Janssen Pharmaceutica Nv Heteroaryl amines as glycogen synthase kinase 3 beta inhibitors (gsk3 inhibitors)
AU2002363174B2 (en) 2001-11-01 2008-09-25 Janssen Pharmaceutica N.V. Amide derivatives as glycogen synthase kinase 3-beta inhibitors
HUP0402245A3 (en) 2001-11-01 2010-03-29 Janssen Pharmaceutica Nv Pyrimidinyl-aminobenzamide derivatives as glycogen synthase kinase 3betha inhibitors, their use, pharmaceutical compositions containing them and process for producing them
EP1448562B1 (en) 2001-11-14 2007-07-25 Ortho-Mcneil Pharmaceutical Corp. Substituted tetracyclic pyrroloquinolone derivatives useful as phosphodiesterase inhibitors
GB0128287D0 (en) 2001-11-26 2002-01-16 Smithkline Beecham Plc Novel method and compounds
FR2832711B1 (fr) 2001-11-26 2004-01-30 Warner Lambert Co Derives de triazolo [4,3-a] pyrido [2,3-d] pyrimidin-5-ones, compositions les contenant, procede de preparation et utilisation
US7973064B2 (en) * 2001-11-27 2011-07-05 The Board Of Trustees Of The University Of Illinois Method and composition for potentiating an opiate analgesic
AU2002365892A1 (en) 2001-11-30 2003-06-17 Merck & Co., Inc. Metabotropic glutamate receptor-5 modulators
WO2003053975A1 (en) 2001-12-13 2003-07-03 Daiichi Suntory Pharma Co., Ltd. Pyrazolopyrimidinone derivatives having pde7-inhibitory activity
EP1458708B1 (en) 2001-12-18 2007-09-26 Merck & Co., Inc. Heteroaryl substituted triazole modulators of metabotropic glutamate receptor-5
JP4286146B2 (ja) 2001-12-18 2009-06-24 メルク エンド カムパニー インコーポレーテッド メタボトロピックグルタミン酸受容体−5のヘテロアリール置換ピラゾール系調節剤
AU2002353186A1 (en) 2001-12-19 2003-06-30 Smithkline Beecham P.L.C. (1-h-indazol-3-yl) -amide derivatives as gsk-3 inhibitors
EP1458385A4 (en) 2001-12-19 2005-12-21 Merck & Co Inc METABOTROPIC GLUTAMATE RECEPTOR 5-HETEROARYL-SUBSTITUTED IMIDAZOLE MODULATORS
SE0104341D0 (sv) 2001-12-20 2001-12-20 Astrazeneca Ab New use
SE0104340D0 (sv) 2001-12-20 2001-12-20 Astrazeneca Ab New compounds
AU2002359162A1 (en) 2001-12-21 2003-07-15 Astrazeneca Ab Use of oxindole derivatives in the treatment of dementia related diseases, alzheimer's disease and conditions associated with glycogen synthase kinase-3
JP4357965B2 (ja) 2001-12-21 2009-11-04 メルク エンド カムパニー インコーポレーテッド メタボトロピックグルタミン酸受容体−5のヘテロアリール置換ピロールモジュレーター
TW200301123A (en) 2001-12-21 2003-07-01 Astrazeneca Uk Ltd New use
DE10163991A1 (de) 2001-12-24 2003-07-03 Merck Patent Gmbh Pyrrolo-pyrimidine
PL208123B1 (pl) 2001-12-27 2011-03-31 Taisho Pharmaceutical Co Ltd Pochodna kwasu 2-amino-3-alkoksy-6-fluorobicyklo [3.1.0] heksano-2, 6-dikarboksylowego, zawierająca ją kompozycja farmaceutyczna i lek, oraz jej zastosowanie
US7550459B2 (en) 2001-12-28 2009-06-23 Acadia Pharmaceuticals, Inc. Tetrahydroquinoline analogues as muscarinic agonists
NZ533567A (en) 2001-12-28 2007-06-29 Acadia Pharm Inc Spiroazacyclic compounds as monoamine receptor for modulating 5-HT2A receptor-mediated events
AU2002359875B2 (en) 2001-12-28 2009-01-08 Acadia Pharmaceuticals Inc. Tetrahydroquinoline analogues as muscarinic agonists
EP1468684A4 (en) 2002-01-22 2008-02-27 Eisai R&D Man Co Ltd SIGMA RECEPTOR BINDING MOLECULE WITH INDANO DERIVATIVE
JPWO2003064389A1 (ja) 2002-01-31 2005-05-26 小野薬品工業株式会社 含窒素二環性化合物およびその化合物を有効成分として含有する薬剤
MXPA04007737A (es) 2002-02-11 2004-10-15 Pfizer Derivados de nicotinamida utiles como inhibidores de fosfodesterasas 4.
AU2003245700A1 (en) 2002-02-12 2003-09-04 Glaxo Group Limited Pyrazolopyridine derivatives
AU2003211428A1 (en) 2002-02-22 2003-09-09 Teijin Limited Pyrrolopyrimidine derivative
TW200306191A (en) 2002-02-22 2003-11-16 Teijin Ltd Pyrrolopyrimidine derivatives
AU2003221500B9 (en) 2002-02-28 2008-11-20 Mitsubishi Pharma Corporation Heteroaryl substituted 2-pyridinyl and 2-pyrimidinyl -6,7,8,9-tetrahydropyrimido[1,2-a] pyrimidin-4-one derivatives
EP1340759A1 (en) 2002-02-28 2003-09-03 Sanofi-Synthelabo 1-[alkyl], 1-[(heteroaryl)alkyl] and 1-[(aryl)alkyl]-7-(pyrimidin-4-yl)-imidazo[1,2-a]pyrimidin-5(1H)-one derivatives
ES2276048T3 (es) 2002-03-05 2007-06-16 Eli Lilly And Company Derivados de purina como inhibidores de cinasa.
ATE368657T1 (de) 2002-03-08 2007-08-15 Lilly Co Eli Pyrrol-2,5-dion derivate und deren verwendung als gsk-3 inhibitoren
JP2005526765A (ja) 2002-03-11 2005-09-08 シエーリング アクチエンゲゼルシャフト Cdk−阻害性2−ヘテロアリール−ピリミジン類、それらの生成及び医薬としての使用
EP1485093B1 (en) 2002-03-12 2010-11-03 Merck Sharp & Dohme Corp. Di-aryl substituted tetrazole modulators of metabotropic glutamate receptor-5
ES2306859T3 (es) 2002-03-13 2008-11-16 Janssen Pharmaceutica Nv Derivados de sulfonil como nuevos inhibidores de histona deacetilasa.
CN100396679C (zh) 2002-03-13 2008-06-25 詹森药业有限公司 用作组蛋白脱乙酰化酶抑制剂的哌嗪基、哌啶基和吗啉基衍生物
WO2003076401A1 (en) 2002-03-13 2003-09-18 Janssen Pharmaceutica N.V. Sulfonylamino-derivatives as novel inhibitors of histone deacetylase
CA2476583C (en) 2002-03-13 2011-07-05 Kristof Van Emelen Aminocarbonyl-derivatives as novel inhibitors of histone deacetylase
ES2284739T3 (es) 2002-03-20 2007-11-16 Societe Des Produits Nestle S.A. Extracto de cacao con bajo contenido en grasa.
GB0206723D0 (en) 2002-03-21 2002-05-01 Glaxo Group Ltd Novel compounds
US7514107B2 (en) 2002-03-21 2009-04-07 Mars, Incorporated Treatment of diseases involving defective gap junctional communication
GB0207246D0 (en) 2002-03-27 2002-05-08 Glaxo Group Ltd Novel compounds
GB0207249D0 (en) 2002-03-27 2002-05-08 Glaxo Group Ltd Novel compounds
SE0302546D0 (sv) 2003-09-24 2003-09-24 Astrazeneca Ab New compounds
SE0200979D0 (sv) 2002-03-28 2002-03-28 Astrazeneca Ab New compounds
AR039209A1 (es) 2002-04-03 2005-02-09 Novartis Ag Derivados de indolilmaleimida
NZ536116A (en) 2002-04-03 2007-01-26 Topotarget Uk Ltd Carbamic acid compounds comprising a piperazine linkage as HDAC inhibitors
SE0201194D0 (sv) 2002-04-19 2002-04-19 Astrazeneca Ab New compounds
GB0210124D0 (en) 2002-05-02 2002-06-12 Merck Sharp & Dohme Therapeutic agents
CA2485527A1 (en) 2002-05-08 2003-11-20 Janssen Pharmaceutica N.V. Substituted pyrroline kinase inhibitors
GB0212048D0 (en) 2002-05-24 2002-07-03 Merck Sharp & Dohme Therapeutic agents
JP2005531609A (ja) 2002-06-05 2005-10-20 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ キナーゼ阻害剤としてのシスインドリル−マレイミド誘導体
ES2312785T3 (es) 2002-06-05 2009-03-01 Janssen Pharmaceutica Nv Pirrolinas sustituidas utiles como inhibidores de quinasa.
CA2490239C (en) 2002-06-19 2011-05-24 Janssen Pharmaceutica N.V. Substituted 2,4-dihydro-pyrrolo (3, 4-b) -quinolin-9-one derivatives useful as phosphodiesterase inhibitors
SI2256108T1 (sl) 2002-07-18 2016-05-31 Janssen Pharmaceutica N.V. Substituirani triazinski kinazni inhibitorji
MXPA05000827A (es) 2002-07-19 2005-08-29 Memory Pharm Corp Inhibidores de fosfodiesterasa 4, incluyendo analogos de anilina y difenilamina n-sustituidos.
JP2005536517A (ja) 2002-07-23 2005-12-02 スミスクライン ビーチャム コーポレーション キナーゼインヒビターとしてのピラゾロピリミジン
EP1534389A2 (en) 2002-07-23 2005-06-01 SmithKline Beecham Corporation Pyrazolopyrimidines as kinase inhibitors
WO2004009597A2 (en) 2002-07-23 2004-01-29 Smithkline Beecham Corporation Pyrazolopyrimidines as protein kinase inhibitors
MXPA05001367A (es) 2002-08-02 2005-04-28 Vertex Pharma Composiciones de pirazol utiles como inhibidores de gsk-3.
DE10239042A1 (de) 2002-08-21 2004-03-04 Schering Ag Makrozyclische Pyrimidine, deren Herstellung und Verwendung als Arzneimittel
JP4881558B2 (ja) 2002-09-04 2012-02-22 シェーリング コーポレイション サイクリン依存性キナーゼインヒビターとしてのピラゾロピリミジン
DE60313872T2 (de) 2002-09-04 2008-01-17 Schering Corp. Pyrazoloä1,5-aüpyrimidine als hemmstoffe cyclin-abhängiger kinasen
EP1400244A1 (en) 2002-09-17 2004-03-24 Warner-Lambert Company LLC New spirocondensed quinazolinones and their use as phosphodiesterase inhibitors
CA2500587A1 (en) 2002-10-04 2004-04-22 The Regents Of The University Of California Screening and therapeutic methods relating to neurogenesis
CN1717391A (zh) 2002-10-21 2006-01-04 希龙公司 糖元合成酶激酶3的抑制剂
GB0226583D0 (en) 2002-11-14 2002-12-18 Cyclacel Ltd Compounds
FR2847253B1 (fr) 2002-11-19 2007-05-18 Aventis Pharma Sa Nouveaux derives de pyridazinones a titre de medicaments et compositions pharmaceutiques les renfermant
US6969702B2 (en) 2002-11-20 2005-11-29 Neuronova Ab Compounds and methods for increasing neurogenesis
US20050009847A1 (en) 2002-11-20 2005-01-13 Goran Bertilsson Compounds and methods for increasing neurogenesis
US20040185429A1 (en) 2002-12-09 2004-09-23 Judith Kelleher-Andersson Method for discovering neurogenic agents
ES2209650B2 (es) 2002-12-09 2006-11-01 Laboratorios Del Dr. Esteve, S.A. Mamiferos no humanos mutantes deficientes en receptores sigma y sus aplicaciones.
GB0229581D0 (en) 2002-12-19 2003-01-22 Cyclacel Ltd Use
US7135493B2 (en) 2003-01-13 2006-11-14 Astellas Pharma Inc. HDAC inhibitor
WO2004065370A1 (en) 2003-01-23 2004-08-05 Crystalgenomics, Inc. Glycogen synthase kinase 3beta inhibitor, composition and process for the preparation thereof
MXPA05008186A (es) 2003-01-31 2005-10-05 Astrazeneca Ab Derivados de quinoxalina saturados y su uso como ligandos receptores de glutamato metabotropico.
US6969716B2 (en) 2003-02-07 2005-11-29 Merck Sharp & Dohme Ltd. 5-phenyl[1,2,4]triazines as ligands for GABA-A α2/α3 receptors for treating anxiety or depression
CA2515132C (en) 2003-02-07 2012-01-03 Vertex Pharmaceuticals Incorporated Heteroaryl substituted pyrroles useful as inhibitors of protein kinases
GB0303319D0 (en) 2003-02-13 2003-03-19 Novartis Ag Organic compounds
EP1454900A1 (en) 2003-03-07 2004-09-08 Sanofi-Synthelabo Process for the preparation of pyridinyl and pyrimidinyl mono-fluorinated beta keto-esters
EP1454909B1 (en) 2003-03-07 2008-08-20 Sanofi Aventis 8'-pyridinyl-dihydrospiro- (cycloalkyl) -pyrimido (1,2-a) pyrimidin-6-one and 8'-pyrimidinyl-dihydrospiro (cycloalkyl) -pyrimido (1,2-a) pyrimidin-6-one derivatives and their use against neurodegenerative diseases
EP1454910A1 (en) 2003-03-07 2004-09-08 Sanofi-Synthelabo Substituted pyrimidinyl-2-(diaza-bicyclo-alkyl)-pyrimidone derivatives
EP1454908B1 (en) 2003-03-07 2008-02-27 Sanofi-Aventis Substituted pyridinyl-2-(diaza-bicyclo-alkyl)-pyrimidinone derivatives
JPWO2004078177A1 (ja) * 2003-03-07 2006-06-08 東レ株式会社 薬物・物質依存治療薬
TWI292318B (en) 2003-03-10 2008-01-11 Hoffmann La Roche Imidazol-4-yl-ethynyl-pyridine derivatives
US20050037983A1 (en) * 2003-03-11 2005-02-17 Timothy Dinan Compositions and methods for the treatment of depression and other affective disorders
US7375228B2 (en) 2003-03-17 2008-05-20 Takeda San Diego, Inc. Histone deacetylase inhibitors
EP1460076A1 (en) 2003-03-21 2004-09-22 Sanofi-Synthelabo Substituted 8-perfluoroalkyl-6,7,8,9-tetrahydropyrimido[1,2-a] pyrimidin-4-one derivatives
EP1613629A1 (en) 2003-03-27 2006-01-11 Pfizer Products Inc. Substituted 4-amino 1,2,4 triazolo 4,3-a quinoxalines
CN1777425A (zh) 2003-03-28 2006-05-24 阿卡蒂亚药品公司 用于疼痛控制的毒蕈碱性m1受体激动剂
CA2519379A1 (en) 2003-04-04 2004-10-21 Dynogen Pharmaceuticals, Inc. Method of treating lower urinary tract disorders
DE10316136A1 (de) 2003-04-09 2004-11-18 Ixys Semiconductor Gmbh Gekapselte Leistungshalbleiteranordnung
US7696198B2 (en) 2003-04-16 2010-04-13 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors
WO2004093802A2 (en) 2003-04-17 2004-11-04 The Board Of Trustees Of The Leland Stanford Junior University Prevention of deficits in neurogenesis with anti-inflammatory agents
US7855212B2 (en) 2003-05-08 2010-12-21 Merck Serono Sa Pyridinyl acetonitriles
GB0311859D0 (en) 2003-05-22 2003-06-25 Merck Sharp & Dohme Therapeutic agents
WO2004106343A2 (en) 2003-05-30 2004-12-09 Ufc Limited Agelastatin derivatives of antitumour and gsk-3beta-inhibiting alkaloids
US7763588B2 (en) 2003-06-13 2010-07-27 The Salk Institute For Biological Studies Method for increasing cognitive function and neurogenesis
DE10328993A1 (de) 2003-06-27 2005-01-20 Bayer Materialscience Ag Blockierte Polyisocyanate
DK1641454T3 (da) 2003-06-27 2009-02-09 Pfizer Prod Inc Pyrazolo[3,4-B]pyridin-6-oner som GSK-3-hæmmere
CA2525245C (en) 2003-06-27 2010-10-19 Pfizer Products Inc. Pyrazolo[3,4-b]pyridin-6-ones as gsk-3 inhibitors
GB0315657D0 (en) 2003-07-03 2003-08-13 Astex Technology Ltd Pharmaceutical compounds
TWI372050B (en) 2003-07-03 2012-09-11 Astex Therapeutics Ltd (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
US7842835B2 (en) 2003-07-07 2010-11-30 Georgetown University Histone deacetylase inhibitors and methods of use thereof
GB0315966D0 (en) 2003-07-08 2003-08-13 Cyclacel Ltd Compounds
NZ545058A (en) 2003-07-16 2008-05-30 Janssen Pharmaceutica Nv Triazolopyrimidine derivatives as glycogen synthase kinase 3 inhibitors
ES2317031T3 (es) 2003-07-16 2009-04-16 Janssen Pharmaceutica Nv Derivados de triazolopirimidina como inhibidores de la glucogeno-sintasa-quinasa 3.
EP2256106B1 (en) 2003-07-22 2015-05-06 Astex Therapeutics Limited 3,4-disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinases (CDK) and glycogen synthase kinase-3 (GSK-3) modulators
PL1651234T3 (pl) 2003-07-25 2008-02-29 Hoffmann La Roche Kompozycja antagonisty mGluR2 i inhibitora AChE do leczenia ostrych i/lub przewlekłych zaburzeń neurologicznych
JP2007500178A (ja) 2003-07-30 2007-01-11 サイクラセル・リミテッド プロテインキナーゼ阻害剤としてのピリジニルアミノ−ピリミジン誘導体
EP1648875A1 (en) 2003-07-30 2006-04-26 Cyclacel Limited 2-aminophenyl-4-phenylpyrimidines as kinase inhibitors
JP2007519393A (ja) 2003-08-05 2007-07-19 ユニバーシティー オブ フロリダ リサーチ ファンデーション, インク. 神経系細胞アッセイ
CN1871240B (zh) 2003-08-26 2012-11-07 帝人制药株式会社 吡咯并嘧啶酮衍生物
PL1664036T3 (pl) * 2003-09-03 2012-04-30 Pfizer Związki benzimidazolonu wykazujące działanie agonistyczne względem receptora 5-ht4
US7820439B2 (en) * 2003-09-03 2010-10-26 Reliance Life Sciences Pvt Ltd. In vitro generation of GABAergic neurons from pluripotent stem cells
TWI339206B (en) 2003-09-04 2011-03-21 Vertex Pharma Compositions useful as inhibitors of protein kinases
EP1668004A1 (en) 2003-09-12 2006-06-14 Applied Research Systems ARS Holding N.V. Benzoxazole acetonitriles
HRP20070527T3 (en) 2003-09-12 2007-12-31 Laboratoires Serono Sa Benzothiazole derivatives for the treatment of diabetes
WO2005026155A1 (en) 2003-09-12 2005-03-24 Applied Research Systems Ars Holding N.V. Benzimidazole acetonitriles
MXPA06004043A (es) 2003-10-10 2006-06-28 Pfizer Prod Inc 2h-[1,2,4]triazolo[4,3-a]pirazinas sustituidas como inhibidores de la glucogeno sintetasa cinasa 3.
RU2006115615A (ru) 2003-10-10 2007-11-27 Марс, Инкорпорейтед (Us) Лечение заболеваний, в патогенез которых вовлечена гиперэкспрессия киназы erbb2
DE10349423A1 (de) 2003-10-16 2005-06-16 Schering Ag Sulfoximinsubstituierte Parimidine als CDK- und/oder VEGF-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
BRPI0415759A (pt) 2003-10-21 2006-12-19 Cyclacel Ltd compostos de pirimidin-4-il-3,4-tiona e uso dos mesmos na terapia
CA2547283C (en) 2003-11-26 2010-11-09 Pfizer Products Inc. Aminopyrazole derivatives as gsk-3 inhibitors
US7855195B2 (en) 2003-12-02 2010-12-21 Pharmaneuroboost N.V. Method of treating mental disorders using D4 and 5-HT2A antagonists, inverse agonists or partial agonists
EP1701725B1 (en) * 2003-12-16 2013-07-31 Relevare Aust. Pty Ltd Compositions comprising flupirtine and an opioid for use in the treatment of neuropathic pain
US20050137234A1 (en) 2003-12-19 2005-06-23 Syrrx, Inc. Histone deacetylase inhibitors
WO2005065681A1 (en) 2003-12-19 2005-07-21 Takeda San Diego, Inc. N- hydroxy-3-(3-(1h-imidazol-2-yl)-phenyl)-acrylamide derivatives and related compounds as histone deacetylase (hdac) inhibitors for the treatment of cancer
BRPI0417749A (pt) 2003-12-22 2007-04-10 Acadia Pharm Inc composto, método de sintese de composto, bibliotecas combinatórias, composições farmacêuticas e métodos de tratamento de disfunções neuropsiquiátricas
AU2005209908A1 (en) 2004-01-30 2005-08-18 Mars, Incorporated Methods and compositions for treating cancer
TWI301760B (en) 2004-02-27 2008-10-11 Merz Pharma Gmbh & Co Kgaa Tetrahydroquinolinones and their use as antagonists of metabotropic glutamate receptors
US7705017B2 (en) 2004-05-03 2010-04-27 En Vivo Pharmaceuticals, Inc. Compounds for treatment of neurodegenerative diseases
EP2021000A2 (en) * 2006-05-09 2009-02-11 Braincells, Inc. Neurogenesis by modulating angiotensin

Also Published As

Publication number Publication date
CA2625210A1 (en) 2007-05-10
EP1942879A1 (en) 2008-07-16
EP2314289A1 (en) 2011-04-27
WO2007053596A1 (en) 2007-05-10
US20070112017A1 (en) 2007-05-17
JP2009513672A (ja) 2009-04-02

Similar Documents

Publication Publication Date Title
US7678808B2 (en) 5 HT receptor mediated neurogenesis
US7985756B2 (en) Modulation of neurogenesis by PDE inhibition
US7998971B2 (en) Combinations containing a 4-acylaminopyridine derivative
US7858611B2 (en) Neurogenesis by modulating angiotensin
EP2314289A1 (en) Gaba receptor mediated modulation of neurogenesis
US20080108574A1 (en) Melanocortin receptor mediated modulation of neurogenesis
US20080103165A1 (en) Ppar mediated modulation of neurogenesis
US20070244143A1 (en) Modulation of neurogenesis by nootropic agents
EP2382975A2 (en) Neurogenesis by modulating angiotensin
US20080103105A1 (en) HMG CoA REDUCTASE MEDIATED MODULATION OF NEUROGENESIS
US20080167363A1 (en) Modulation of Neurogenesis By Melatoninergic Agents
US20100216805A1 (en) Modulation of neurogenesis using d-cycloserine combinations
US20080171750A1 (en) Modulation Of Neurogenesis With Use of Modafinil

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application